Next Article in Journal
Synthesis and Characterization of Inorganic-Organic Derivatives of Layered Perovskite-like Niobate HSr2Nb3O10 with n-Amines and n-Alcohols
Next Article in Special Issue
In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment
Previous Article in Journal
Improving the Luminescence and Stability of Carbon-Centered Radicals by Kinetic Isotope Effect
Previous Article in Special Issue
Anti-Inflammatory Potential of Seasonal Sonoran Propolis Extracts and Some of Their Main Constituents
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 12
10.3390/molecules28124806
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Novel Tryptanthrin Derivatives with Selectivity as c–Jun N–Terminal Kinase (JNK) 3 Inhibitors

by
Igor A. Schepetkin
1,
Oleksander S. Karpenko
2,
Anastasia R. Kovrizhina
3,
Liliya N. Kirpotina
1,
Andrei I. Khlebnikov
3,
Stepan I. Chekal
4,
Alevtyna V. Radudik
2,4,
Maryna O. Shybinska
2 and
Mark T. Quinn
1,*
1
Department of Microbiology and Cell Biology, Montana State University, Bozeman, MT 59717, USA
2
O.V. Bogatsky Physico-Chemical Institute, National Academy of Sciences of Ukraine, 65080 Odesa, Ukraine
3
Kizhner Research Center, Tomsk Polytechnic University, Tomsk 634050, Russia
4
Department of Organic Chemistry, Faculty of Chemistry and Pharmacy, Odesa I.I. Mechnikov National University, 65082 Odesa, Ukraine
*
Author to whom correspondence should be addressed.
Molecules 2023, 28(12), 4806; https://doi.org/10.3390/molecules28124806
Submission received: 15 May 2023 / Revised: 9 June 2023 / Accepted: 12 June 2023 / Published: 16 June 2023
(This article belongs to the Special Issue Biological Activity of Natural and Synthetic Compounds 2.0)
Browse Figures
Versions Notes

Abstract

:
The c-Jun N-terminal kinase (JNK) family includes three proteins (JNK1-3) that regulate many physiological processes, including cell proliferation and differentiation, cell survival, and inflammation. Because of emerging data suggesting that JNK3 may play an important role in neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease, as well as cancer pathogenesis, we sought to identify JNK inhibitors with increased selectivity for JNK3. A panel of 26 novel tryptanthrin-6-oxime analogs was synthesized and evaluated for JNK1-3 binding (Kd) and inhibition of cellular inflammatory responses. Compounds 4d (8-methoxyindolo[2,1-b]quinazolin-6,12-dione oxime) and 4e (8-phenylindolo[2,1-b]quinazolin-6,12-dione oxime) had high selectivity for JNK3 versus JNK1 and JNK2 and inhibited lipopolysaccharide (LPS)-induced nuclear factor-κB/activating protein 1 (NF-κB/AP-1) transcriptional activity in THP-1Blue cells and interleukin-6 (IL-6) production by MonoMac-6 monocytic cells in the low micromolar range. Likewise, compounds 4d, 4e, and pan-JNK inhibitor 4h (9-methylindolo[2,1-b]quinazolin-6,12-dione oxime) decreased LPS-induced c-Jun phosphorylation in MonoMac-6 cells, directly confirming JNK inhibition. Molecular modeling suggested modes of binding interaction of these compounds in the JNK3 catalytic site that were in agreement with the experimental data on JNK3 binding. Our results demonstrate the potential for developing anti-inflammatory drugs based on these nitrogen-containing heterocyclic systems with selectivity for JNK3.

1. Introduction

JNKs are members of the mitogen-activated protein kinase (MAPK) family that regulates many physiological processes [1,2]. The JNK pathway is a highly complex pathway within the MAPK signaling network [3]. Activation of JNKs can be induced by a number of proteins, such as other MAPKs and G protein-coupled receptors (GPCRs), which transmit information into the JNK signaling pathway [4]. Despite their name, activated JNKs do not only phosphorylate c-Jun, and close to 100 JNK substrates are known [5]. However, c-Jun is a major substrate for JNKs, and its phosphorylation is closely tied to activator protein 1 (AP-1) activation. Previous studies have shown that JNKs play an important role in the regulation of signaling pathways involved in inflammation, apoptosis, and necrosis [6,7,8,9]. Indeed, JNK signaling is involved in a wide range of diseases, including multiple sclerosis, rheumatoid arthritis, osteoarthritis, insulin resistance, inflammatory bowel diseases, cancer, stroke, renal ischemia, essential hypertension, Alzheimer’s disease, and Parkinson’s disease [10,11,12,13,14,15,16,17,18,19,20,21]. Therefore, JNKs have become important therapeutic targets and many groups have sought to develop inhibitors for these targets [22,23,24]. Nevertheless, further development of novel JNK inhibitors with clinical value is essential.
The human genome contains three closely related JNK genes (JNK1, JNK2, and JNK3), with each gene encoding multiple isoforms [25]. While JNK1 and JNK2 are expressed in a variety of tissues, JNK3 expression has been reported to be limited mainly to neuronal tissue and, to a lesser extent, heart and testes [26,27]. Thus, most early studies on JNK3 function have focused primarily on its role in brain and neural tissues. However, more recent studies suggest that JNK3 is involved in a wider range of tissues and pathologies. For example, JNK3 has been reported to be expressed in human and mouse pancreatic β-cells [28], human CD14+ monocytes [29], normal human epithelial cells [30], normal human MRC-5 fibroblasts, and human thyroid cells and tissue [31]. While the function of JNK3 in these tissues is still being defined, several reports have suggested important regulatory functions. JNK3 has been reported to play an important role in the circulatory system, including in angiogenesis [32]. Likewise, it has been reported that β-arrestin 2 can regulate macrophage function via JNK3 [33]. Additional studies on the patterns of JNK3 expression in various tissues may find that JNK3 has both compensatory and opposing functions that affect the ability of JNK1 and JNK2 to carry out their characteristic activities [34].
Recent research has indicated that JNK3 may play an important role in cancer. For example, JNK3 was found to be expressed in human ovarian cancer SKOV3/DDP cells [35], human hepatocellular carcinoma cells [36], human small-cell lung cancer cells [37], human esophageal squamous cell carcinoma cells [38], and HeLa cells [39]. Notably, Gorogh et al. [40] reported that JNK3 was capable of conveying chemotherapy resistance and survival in HNSCC (head and neck squamous cell carcinoma) cells. Likewise, analysis of prostate cancer clinical samples indicated that high intratumor JNK3 levels correlated with a worse prognosis [41]. In human breast cancer samples and tumor cell lines, JNK3, but not the other JNK isoforms, responded to amyloid precursor protein (APP) signaling, and subsequent JNK3 phosphorylation facilitated epithelial–mesenchymal transition of breast cancer cells [42]. Finally, high basal levels of JNK3 expression were present in oral keratinocyte cell lines, and invasion by these cells was found to be primarily JNK3-dependent [43].
More than 100 JNK inhibitors have been identified, with some even evaluated in clinical trials, yet fewer than ten JNK3-selective inhibitors have been reported [44,45,46,47]. Tryptanthrin (TRYP) (indolo[2,1-b]quinazolin-6,12-dione) is an alkaloid that can be isolated from higher plants and several marine organisms (for a review, see [48]). We previously found that tryptanthrin-6-oxime (TRYP-Ox) derivatives and their analogs with an 11H-indeno[1,2-b]quinoxalin-11-one scaffold were effective JNK inhibitors [49,50,51,52] (see Figure 1). Notably, the TRYP-Ox derivative TRYP–1e had ~10-fold greater selectivity for JNK3 binding versus JNK1/JNK2 [49] (Figure 1). In the present studies, we synthesized a new series of twenty-six TRYP-Ox derivatives in an effort to identify novel and isoform-selective JNK inhibitors. Specifically, we evaluated the effects of substituents in the tetracyclic scaffold of TRYP-Ox on enzymatic binding, cell-mediated inflammatory responses, and c-Jun phosphorylation.

2. Results and Discussion

2.1. Synthesis of Tryptanthrin Derivatives

Our prior analysis of indenoquinoxaline and tryptanthrin derivatives demonstrated that an oxime group was essential for JNK inhibition, and compounds lacking the oxime had little or no effect on JNK activity [49,50,53,54]. Therefore, we examined the effect of adding different substituents to the tetracyclic scaffold of tryptanthrin while maintaining the oxime group. JNK binding and inhibitory activity of these TRYP-Ox derivatives were evaluated.
For compound synthesis, substituted isatins 1a–l and isatoic anhydrides 2a–g (see Table 1) were refluxed in boiling toluene (Scheme 1, path A) to obtain the corresponding ketones 3a–n. Poor yields were observed when electron-withdrawing substituents were present in position 8 (NO2, Br), and only traces of target compounds were obtained when starting with 7-substituted isatins.
The procedure shown in path B, described previously in [55], was used for synthesis of pseudo-symmetric ketones 3o–u. Corresponding target compounds were obtained in low yields, although low yields were compensated for by simplicity of the procedure. Using 7-methyl, 7-methoxy, or 5-nitro substituted isatins for synthesis via path A gave just traces of the corresponding target products.
Oximes 4a–u were synthesized from ketones 3a–u by refluxing in pyridine and then treating with excess of hydroxylamine hydrochloride. The general yields of this procedure were high. Minor impurities and traces of starting compounds were removed by washing with water or boiling toluene, and with recrystallization from 1,4-dioxane.
We also considered the possibility of obtaining active tryptanthrin derivatives by modifying the oxime fragment using O-substitution [50]. One of the methods for obtaining aryl (Ar) derivatives with an isonitroso group (Ar=N-OR) is the reaction of tryptanthrin with O-substituted hydroxylamine hydrochlorides. However, this reaction is limited in the choice of reagents in so far as O-substituted hydroxylamines mainly have nonionic groups (e.g., alkyl and halogen derivatives) [56]. It is worth noting that the dependence of reaction mechanisms on the substrates used and reaction conditions has not been previously described in the literature.
O-substitution reactions were performed to obtain compounds 5a–e in a superbasic medium (KOH/DMSO), which revealed dependence of the reactivity of oximes on these conditions. We considered a number of acylating and alkylating reagents, such as methyl chloroformate, propargyl chloroformate, piperonyl chloride, ethyl ester of monochloroacetic acid, and diethyl ester of bromomalonic acid. Synthesis of oxime analogues 5c–e by acyl substitution in the KOH/DMSO system (Scheme 2, path A) failed. Presumably, this was due to the fact that DMSO, being an aprotic solvent, easily solvates potassium cations, while anions are only slightly solvated, which in turn leads to superbasic properties of the medium [57] and a decrease in stability of the intermediate in the acyl substitution reaction. Another reason why it was not possible to carry out reactions with chloroformates in the KOH/DMSO system may be the basic hydrolysis of formates to salts of organic acids and reaction products to the starting oximes. However, the acyl substitution occurred under milder conditions, such as in pyridine, which simultaneously acts as a solvent and a base (Scheme 2, path B).
Nucleophilic substitution in the synthesis of compounds 5a–b was facilitated in the superbasic medium, probably due to an easier formation of the oximate nucleophile. Completion of the reactions shown in Scheme 2 was monitored with TLC (eluent: chloroform).

2.2. Binding Affinity of the Compounds for JNK1-3

All compounds were evaluated for their ability to bind to JNK1-3 using the KINOMEscan platform [58]. This method was validated for the structurally related 11H-indeno[1,2-b]quinoxalin-11-one JNK inhibitor IQ-1S by an independent fluorescence polarization-based competition binding assay [59].
One compound (4h) had high affinity for JNK, with Kd values in the submicromolar range for all three JNK isoforms, whereas seven compounds (4a, 4d, 4e, 4i, 4k, 4m, and 4n) were selective for JNK3 and did not bind to either JNK1 or JNK2 (Table 2). Note that four compounds with relatively high selectivity (selectivity index > 7) had a single substituent at R2 (i.e., NO2, Br, OMe, and phenyl in compounds 4a, 4b, 4d, and 4e, respectively). Moving the methyl group in compound 4g, which had relatively high selectivity for JNK3, from R1 to R3 led to compound 4h, which had low selectivity but high binding activity for all JNK isoforms. Moving NO2 from R2 (compound 4a) to R5 (compound 4n) or R6 (compound 4m) decreased binding affinity for JNK3 and reduced selectivity. Introduction of an additional OMe group in compound 4d or an additional Me in compound 4g led to inactive compounds 4q and 4p, respectively. Similarly, introduction of additional Br in compounds 4a, 4b, and 4k, led to inactive compounds 4f, 4t, and 4s, respectively, which is probably due to the bulkiness of the molecule and decreased complementarity to the binding site.
Among the O-substituted TRYP-Ox derivatives, compounds 5a and 5b were inactive (5a) or had low binding activity (5b) for all JNK isoforms, whereas the other three compounds 5c–e had relatively high affinity, with Kd values in the submicromolar range for all three JNK isoforms, indicating low JNK isoform selectivity (Table 2).

2.3. Activity of Compounds in Monocytic Cells

Prior to evaluation of the compounds in cell-based assays, we measured their cytotoxicity in human monocytic THP-1Blue and MonoMac-6 cells during a 24 h incubation. Seven compounds (4a, 4f, 4i, 4j, and 4r–t) were cytotoxic in both cell lines, with IC50 values ranging from 0.17 to 49.1 μM (Table 3). Compounds 4k and 4n exhibited cytotoxicity in THP-1Blue cells, and compounds 4c and 5e were cytotoxic for MonoMac-6 cells. Thus, these compounds were all excluded from subsequent testing in these cell lines.
The JNK pathway can be activated through Toll-like receptor 4 (TLR4), leading to the activation of transcription factors NF-κB and AP-1 [60,61]. Thus, to assess the anti-inflammatory activity of our derivatives, the remaining non-cytotoxic compounds were evaluated for their ability to inhibit lipopolysaccharide (LPS)-induced NF-κB/AP-1 reporter activity and IL-6 production in THP-1Blue and MonoMac-6 cells, respectively. Compounds 4c–e, which contain ethyl, methoxy, and phenyl groups at R2, and compound 4h, which has a methyl group at R3, were the most potent inhibitors of NF-κB/AP-1 reporter activity in THP-1Blue cells, with IC50 values < 2 μM (Table 3). As an example, the dose-dependent inhibition of LPS-induced NF-κB/AP-1 reporter activity by compounds 4d and 4e is shown in Figure 2A.
Six of the compounds (4d, 4e, 4h, 4k, 4l, and 4o) were also potent inhibitors of IL-6 production in MonoMac-6 cells, with IC50 values < 1 μM. As an example, the dose-dependent inhibition of LPS-induced IL-6 production by compounds 4d and 4e is shown in Figure 2B. Note that 4d and 4e were highly specific for JNK3, whereas compound 4h was a pan-JNK inhibitor. Thus, these three compounds were selected for subsequent analysis in MonoMac-6 cells for their ability to inhibit LPS-induced c-Jun phosphorylation.
MonoMac-6 cells were pretreated with compounds 4d, 4e, 4h, or a structural analog IQ-1S with demonstrated potent JNK inhibitory activity as a positive control [53]. After 30 min pretreatment with the compounds, the cells were stimulated with LPS (500 ng/mL), and the level of phospho-c-Jun (S63) was determined by a sandwich ELISA. All of these compounds dose-dependently inhibited c-Jun phosphorylation (Figure 3), directly confirming JNK inhibition.

2.4. Molecular Modeling

To gain insight into interactions of the investigated compounds with JNK and explain some of the observations made in our structure–activity relationship analysis, we performed molecular docking of selected compounds and TRYP-Ox into the JNK3 binding site (PDB: 1PMV) using Molegro Virtual Docker 6.0 (MVD) software. Note that these compounds exist as mixtures of Z and E isomers with respect to the exocyclic C=N bond, and these geometric isomers are prone to interconversion [62,63]. MolDock docking scores for the docking poses of both isomers of these compounds are shown in Table 4.
Compounds 4a (Z), 4b (Z), and 4d (E) had the highest docking scores and were located within the JNK3 binding site, similar to the co-crystallized pan-JNK inhibitor SP600125. As an example, see the docking pose of the methoxy derivative 4d (E) in Figure 4A, where it forms a strong H-bond to Lys93 with its oxime oxygen atom. In this binding mode, the quinazolone moiety coincides with the experimentally determined position of SP600125 in PDB structure 1PMV [64]. In contrast, the inactive compound 4q (Z), which contains two methoxy groups and did not have affinity for any of the three JNK isoforms, had a different location in the JNK3 binding site. As shown in Figure 4B, molecular docking results suggested that compound 4q (Z) could be H-bonded to Ser193 and deviate significantly from the plane of SP600125. This difference is likely due to steric effects introduced by adding the second methoxy group in the tryptanthrin scaffold. In the docking pose of compound 4d (E), the benzene ring in the azaindene moiety is located near Met149, Asp150, and Ala151 of JNK (Figure 4A), and the additional methoxy substituent in this ring would cause a steric clash with neighboring residues. Hence, compound 4q (Z) should be shifted and rotated within the binding site with respect to compound 4d (E), which leads to a lower DS value (Table 4).
We also conducted molecular docking of the compounds found to be most potent in the cell-based assays (4c–e,h; see Table 3) to evaluate their relative positions within the JNK3 binding site. The superimposed final docking poses for these compounds are shown in Figure 5 and show that these compounds occupy approximately the same area of space in binding to the enzyme. Additionally, they overlap significantly with the position of co-crystallized SP600125 present in the PDB 1PMV structure.
To evaluate the relative energies of geometric isomers and the barrier for Z,E-isomerization, we performed DFT calculations of relative Gibbs free energies for Z- and E-isomers of compound 4d in DMSO using the M06-2X functional, which is suitable for evaluation of thermochemical properties of organic compounds [65]. We found that the E-isomer had a slightly higher thermodynamic stability, with its Gibbs energy being 0.96 kcal/mol lower than that of the Z-isomer. Using the DFT method, we also found that E→Z isomerization occurs via in-plane inversion of the oxime nitrogen atom, similar to other molecules containing a C=N bond [66]. With the small difference in Gibbs energies indicated above, both isomers can be present in the solution [67]. However, the calculated isomerization barrier ΔG≠ for oxime 4d was 49.5 kcal/mol in DMSO, indicating that isomerization in solution should be a slow process in accordance with one of the isomers predominating in the synthesized samples (see the NMR data in Section 3). However, isomerization may occur during interaction of the investigated tryptanthrin oximes with the JNK binding site. Z,E-isomerization of these oximes in solution and on binding to the enzyme is a subject of our future studies.

3. Experimental Section

3.1. Chemistry

Starting materials for the synthesis of 4a–u were obtained from Enamine (Kiev, Ukraine), while starting materials for synthesis of 5a–e were obtained from Merck. Tryptanthrin (indolo[2,1-b]quinazolin-6,12-dione) was purchased from Combi-Blocks (San Diego, CA, USA). Reaction progress was monitored by thin-layer chromatography (TLC) with UV detection using pre-coated silica gel 60, F254 plates (Merck, Rahway, NJ, USA). Structures of the synthesized compounds were confirmed on the basis of analytical and spectral data. The melting points (mp) were determined using an electrothermal Mel-Temp capillary melting point apparatus and an SMP30 melting point apparatus, with a heating rate of 3.0 °C/min. Elemental analysis was performed with a Carlo Erba instrument. LC-HRMS analysis was performed on an Agilent chromatograph with a 6538 UHD Accurate-Mass Q-TOF detector (ESI in positive mode). EI-MS spectra were obtained from a MX-1321 instrument (Tsourse = 220 °C, Eionisation = 70 eV). NMR spectra were recorded on Bruker spectrometers (operating frequencies: 400 and 600 MHz for 1H, 100 and 150 MHz for 13C, and 280 MHz for 19F). IR spectra were recorded on a Nicolet 5700 FT-IR spectrometer with KBr pellets.
TRYP-Ox was prepared according to the literature [50,68], and IQ-1S was synthesized as described previously [53].

3.1.1. General Procedure for Synthesis of Ketones 3a–3n

A solution of corresponding isatin (1 mmol), corresponding isatoic anhydride (1 mmol), and triethylamine (5 mmol) was refluxed in ~10 mL of toluene for 1–4 h. Reaction progress was monitored with TLC using chloroform as the developing solvent. After a completion of the reaction, the mixture was cooled to the room temperature, and the precipitated product was filtered off and washed with methanol. The final products were purified by recrystallization from 1,4-dioxane.
8-Nitroindolo[2,1-b]quinazolin-6,12-dione (3a). Yield 38%, mp > 250 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.80 (m, 1H), 8.01 (d, J = 3.6 Hz, 1H), 8.38 (d, J = 7.8 Hz, 1H), 8.57 (d, J = 2.4 Hz, 1H), 8.70 (d, J = 9.0 Hz, 1H), 8.74 (dd, J1 = 9.0 Hz, J2 = 2.4 Hz, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 118.15, 119.97, 123.30, 123.62, 127.71, 130.59, 130.83, 133.07, 136.27, 145.72, 146.11, 146.60, 149.64, 158.40, 181.32. C15H7N3O4. M.W. 293.23. Mass spectrum (EI) m/z (I, %): 293 (100), 265 (15), 219 (25).
8-Bromoindolo[2,1-b]quinazolin-6,12-dione (3b). Yield 42%, mp = 285 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.76 (m, 1H), 7.97 (d, J = 3.6 Hz, 2H), 8.07 (m, 2H), 8.34 (d, J = 7.8 Hz, 1H), 8.43 (d, J = 8.4 Hz, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 119.41, 119.61, 123.59, 124.73, 127.47, 127.58, 130.46, 130.52, 135.82, 140.18, 145.27, 146.87, 158.11, 181.68. C15H7BrN2O2. M.W. 327.13. Mass spectrum (EI) m/z (I, %): 328 (800), 326 (100), 300 (30), 298 (30).
8-Ethylindolo[2,1-b]quinazolin-6,12-dione (3c). Yield 35%, mp = 221 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 1.23 (t, J = 7.8 Hz, 3H), 2.72 (q, J = 7.8 Hz, 2H), 7.17 (m, 3H), 7.94 (m, 2H), 8.30 (d, J = 7.8 Hz, 1H), 8.36 (d, J = 8.4 Hz, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 15.92, 28.01, 117.36, 122.80, 123.79, 124.11, 127.33, 130.25, 130.34, 135.51, 137.63, 143.41, 144.59, 145.67, 146.92, 157.94, 182.94. C17H12N2O2. M.W. 276.29. Mass spectrum (EI) m/z (I, %): 276 (70), 261 (100), 233 (20).
8-Methoxyindolo[2,1-b]quinazolin-6,12-dione (3d). Yield 59%, mp = 265 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 3.88 (s, 3H), 7.42 (m, 2H), 7.41 (m, 1H), 7.94 (d, J = 4.2 Hz, 2H), 8.31 (d, J = 7.8 Hz, 1H), 8.38 (d, J = 9.0 Hz, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 56.51, 108.95, 118.72, 123.86, 123.89, 124.22, 127.28, 130.30, 130.37, 135.44, 140.40, 145.85, 146.91, 157.77, 158.47, 182.83. C16H10N2O3. M.W. 278.26. Mass spectrum (EI) m/z (I, %): 278 (100), 263 (40), 235 (20).
8-Phenylindolo[2,1-b]quinazolin-6,12-dione (3e). Yield 65%, mp = 215–246 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.43 (1H, dd, J1 = 7.3 Hz, J2 = 7.3 Hz), 7.51 (2H, dd, J1 = 8.1 Hz, J2 = 8.1 Hz), 7.74 (m, 1H), 7.79 (2H, d, J = 7.3 Hz), 7.95 (2H, m), 8.12 (1H, d, J = 2.1 Hz), 8.19 (1H, dd, J1 = 8.1 Hz, J2 = 2.1 Hz), 8.34 (1H, d, J = 7.7 Hz), 8.54 (1H, d, J = 8.3 Hz). 13C NMR (150 MHz, DMSO-d6) δ ppm: 117.5, 122.2, 122.3, 123.0, 123.3, 126.7, 126.9, 128.2, 129.1, 129.8, 135.2, 135.9, 138.1, 138.7, 145.1, 145.3, 146.4, 157.6, 182.4. C21H12N2O2. M.W. 324.33. Mass spectrum (EI) m/z (I, %): 324 (100), 296 (20).
2-Bromo-8-nitroindolo[2,1-b]quinazolin-6,12-dione (3f). Yield 29%, mp > 300 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.95 (1H, d, J = 8.6 Hz), 8.17 (1H, dd, J1 = 8.6 Hz, J2 = 2.4 Hz), 8.44 (1H, d, J = 7.8 Hz), 8.56 (1H, d, J = 2.4 Hz), 8.66 (1H, d, J = 8.8 Hz), 8.73 (1H, dd, J1 = 8.8 Hz, J2 = 2.4 Hz). 13C NMR (150 MHz, DMSO-d6) δ ppm: 117.7, 119.5, 123.1, 123.3, 124.4, 129.4, 132.2, 132.6, 138.6, 145.2, 145.5, 145.8, 148.8, 156.7, 180.5. C15H6BrN3O4. M.W. 372.13. Mass spectrum (EI) m/z (I, %): 373 (100), 371 (100), 343 (10), 341 (10).
7-Methylindolo[2,1-b]quinazolin-6,12-dione (3g). Yield 61%, mp = 252–253 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.52 (1H, dd, J1 = 7.5 Hz, J2 = 7.5 Hz), 7.91 (2H, m), 8.17 (1H, d, J = 8.8 Hz), 8.47 (1H, d, J = 8.1 Hz), 8.66 (1H, dd, J1 = 8.8 Hz, J2 = 2.6 Hz), 8.95 (1H, d, J = 2.6 Hz). 13C NMR (150 MHz, DMSO-d6) δ ppm: 122.4, 127.4, 127.6, 129.0, 130.3, 132.7, 134.4, 136.7, 143.2, 150.9, 152.3, 152.6, 155.9, 162.2, 187.2. C16H10N2O2. M.W. 262.26. Mass spectrum (EI) m/z (I, %): 262 (100), 234 (10).
9-Methylindolo[2,1-b]quinazolin-6,12-dione (3h). Yield 58%, mp = 255−256 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 2.5 (3H, s), 7.26 (1H, d, J = 7.7 Hz), 7.71 (1H, m), 7.75 (1H, d, J = 7.7 Hz), 7.92 (2H, m), 8.28 (2H, m). 13C NMR (150 MHz, DMSO-d6) δ ppm: 22.4, 117.3, 117.4, 119.9, 123.2, 124.6, 126.9, 127.5, 129.7, 129.8, 135.1, 145.3, 146.3, 149.4, 157.6, 181.7. C16H10N2O2. M.W. 262.26. Mass spectrum (EI) m/z (I, %): 262 (100), 234 (30).
2-Trifluoromethylindolo[2,1-b]quinazolin-6,12-dione (3i). Yield 63%, mp = 357–358 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.51 (1H, dd, J1 = 7.5 Hz, J2 = 7.5 Hz), 7.91 (2H, m), 8.16 (1H, d, J = 8.4 Hz), 8.27 (1H, dd, J1 = 2.0 Hz, J2 = 8.4 Hz), 8.47 (1H, d, J = 8.1 Hz), 8.54 (1H, d, J = 0.9 Hz). 13C NMR (150 MHz, DMSO-d6) δ ppm: 117.1, 122.1, 122.6, 123.7, 123.9, 124.4, 124.9, 127.2, 129.1, 131.2, 137.9, 145.7, 146.7, 149.1, 157.0, 182.1. 19F NMR (376 MHz, DMSO) δ ppm: −61.10 (s). C16H7F3N2O2. M.W. 316.23. Mass spectrum (EI) m/z (I, %): 316 (100), 288 (50), 266 (10).
2-Bromoindolo[2,1-b]quinazolin-6,12-dione (3j). Yield 46%, mp = 366–367 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.49 (1H, dd, J1 = 7.6 Hz, J2 = 7.6 Hz), 7.88 (3H, m), 8.11 (1H, ddd, J1 = 8.6 Hz, J2 = 2.0 Hz, J3 = 2.0 Hz), 8.39 (1H, d, J = 2.0 Hz), 8.46 (1H, d, J = 8.6 Hz). 13C NMR (150 MHz, DMSO-d6) δ ppm: 117.6, 122.7, 123.3, 125.3, 125.4, 127.6, 129.6, 132.5, 138.3, 138.5, 145.9, 146.0, 146.2, 157.1, 182.7. C15H7BrN2O2. M.W. 327.13. Mass spectrum (EI) m/z (I, %): 328 (800), 326 (100), 300 (20), 298 (20).
3-Bromoindolo[2,1-b]quinazolin-6,12-dione (3k). Yield 59%, mp = 290–291 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.49 (1H, dd, J1 = 4.5 Hz, J2 = 4.5 Hz), 7.88 (3H, m), 8.21 (2H, m), 8.45 (1H, d, J = 8.1 Hz), 7.48 (1H, dd, J1 = 7.5 Hz, J2 = 7.5 Hz). 13C NMR (150 MHz, DMSO-d6) δ ppm: 117.0, 122.1, 122.5, 124.9, 127.0, 128.6, 128.7, 132.0, 132.8, 137.9, 145.8, 146.1, 147.7, 157.3, 182.2. C15H7BrN2O2. M.W. 327.13. Mass spectrum (EI) m/z (I, %): 328 (100), 326 (95), 300 (30), 298 (30).
3-Fluoroindolo[2,1-b]quinazolin-6,12-dione (3l). Yield 53%, mp = 289 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.48 (1H, dd, J1 = 7.5 Hz, J2 = 7.5 Hz), 7.6 (1H, ddd, J1 = 8.7 Hz, J2 = 8.7 Hz, J3 = 2.0 Hz), 7.81 (1H, dd, J1 = 9.7 Hz, J2 = 2.5 Hz), 7.88 (2H, m), 8.37 (1H, dd, J1 = 8.7 Hz, J2 = 6.1 Hz), 8.46 (1H, d, J = 7.9 Hz). 13C NMR (150 MHz, DMSO-d6) δ ppm: 115.3, 117.0, 118.0, 120.3, 122.1, 124.8, 127.0, 129.9, 137.8, 145.9, 148.7, 157.1, 165.0, 166.6, 182.2. 19F NMR (376 MHz, DMSO) δ ppm: −103.33 (s). C15H7FN2O2. M.W. 266.23. Mass spectrum (EI) m/z (I, %): 266 (100), 238 (70), 210 (40).
3-Nitroindolo[2,1-b]quinazolin-6,12-dione (3m). Yield 59%, mp > 300 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.54 (1H, dd, J1 = 6.8 Hz, J2 = 6.8 Hz), 7.91 (2H, m), 8.45 (1H, dd, J1 = 8.6 Hz, J2 = 2.2 Hz), 8.49 (1H, d, J = 7.9 Hz), 8.56 (1H, d, J = 8.6 Hz), 8.67 (1H, d, J = 2.2 Hz). 13C NMR (150 MHz, DMSO-d6) δ ppm: 117.5, 119.5, 122.4, 127.4, 128.6, 129.7, 130.2, 132.9, 134.2, 137.4, 147.7, 150.9, 151.9, 152.3, 156.7. C15H7N3O4. M.W. 293.23. Mass spectrum (EI) m/z (I, %): 293 (100), 265 (20), 247 (10), 219 (10).
2-Nitroindolo[2,1-b]quinazolin-6,12-dione (3n). Yield 33%, mp > 300 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.52 (1H, dd, J1 = 7.5 Hz, J2 = 7.5 Hz), 7.91 (2H, m), 8.17 (1H, d, J = 8.8 Hz), 8.47 (1H, d, J = 8.1 Hz), 8.66 (1H, dd, J1 = 8.8 Hz, J2 = 2.6 Hz), 8.95 (1H, d, J = 2.6 Hz). 13C NMR (150 MHz, DMSO-d6) δ ppm: 122.4, 127.4, 127.6, 129.0, 130.3, 132.7, 134.4, 136.7, 143.2, 150.9, 152.3, 152.6, 155.9, 162.2, 187.2. C15H7N3O4. M.W. 293.23. Mass spectrum (EI) m/z (I, %): 293 (100), 265 (20), 247 (10), 219 (25).

3.1.2. General Procedure for Synthesis of Ketones 3o–3u

Twenty mL of DMSO was added to the corresponding isatin (5 mmol), the mixture was heated to dissolve the isatin, and potassium phosphate (5 mmol) was added. After cooling, tert-butyl hydroperoxide (5 mmol, 550 μL of 70% aqueous solution) was added, and the mixture was left at room temperature for at least 20 h. The progress of the reaction was monitored with TLC, using chloroform as the developing solvent. The reaction mixture was poured into 100 mL of water and left to precipitate overnight. The precipitate was filtered off, washed with water (2 × 5 mL), and dried at 105 °C. The final products were purified by recrystallization from 1,4-dioxane.
2,8-Dimethylindolo[2,1-b]quinazolin-6,12-dione (3o). Yield 20%, mp = 236–237 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 2.39 (3H, s), 2.51 (3H, s), 7.65 (2H, m), 7.74 (1H, dd, J1 = 8.2 Hz, J2 = 1.8 Hz), 7.82 (1H, d, J = 8.3 Hz), 8.09 (1H, d, J = 1.8 Hz), 8.33 (1H, d, J = 8.1 Hz). 13C NMR (150 MHz, DMSO-d6) δ ppm: 20.4, 21.0, 116.8, 122.3, 123.1, 124.7, 126.4, 129.7, 136.1, 136.6, 138.0, 140.2, 143.9, 144.4, 144.5, 157.4, 182.4. C17H12N2O2. M.W. 276.30. Mass spectrum (EI) m/z (I, %): 276 (100), 248 (30)
1,7-Dimethylindolo[2,1-b]quinazolin-6,12-dione (3p). Yield 8%, mp = 290–291 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 2.62 (s, 3H), 2.87 (3H, s), 7.24 (1H, d, J = 7.7 Hz), 7.47 (1H, m), 7.68 (1H, dd, J1 = 7.8 Hz, J2 = 7.8 Hz), 7.74 (2H, m), 8.32 (1H, d, J = 8.1 Hz). 13C NMR (150 MHz, DMSO-d6) δ ppm: 17.7, 22.6, 114.5, 119.9, 121.4, 128.2, 128.6, 132.4, 134.0, 136.9, 139.7, 141.4, 144.5, 146.3, 148.0, 158.5, 183.1. C17H12N2O2. M.W. 276.30. Mass spectrum (EI) m/z (I, %): 276 (100), 248 (20).
2,8-Dimethoxylindolo[2,1-b]quinazolin-6,12-dione (3q). Yield 29%, mp = 260–261 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 3.86 (3H, s), 3.95 (3H, s), 7.38 (1H, d, J = 2.7 Hz), 7.42 (1H, dd, J1 = 8.6 Hz, J2 = 2.7 Hz), 7.51 (1H, dd, J1 = 8.8 Hz, J2 = 2.9 Hz), 7.7 (1H, d, J = 3.0 Hz), 7.87 (1H, d, J = 9.0 Hz), 8.37 (1H, d, J = 8.7 Hz). 13C NMR (150 MHz, DMSO-d6) δ ppm: 61.2, 113.4, 113.6, 123.5, 128.6, 128.9, 130.1, 136.9, 137.0, 145.0, 145.7, 148.8, 162.1, 163.2, 165.6, 187.4. C17H12N2O4. M.W. 308.30. Mass spectrum (EI) m/z (I, %): 308 (100), 293 (40).
3,9-Dimethoxylindolo[2,1-b]quinazolin-6,12-dione (3r). Yield 62%, mp > 300 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 3.94 (3H, s), 3.97 (3H, s), 6.97 (1H, dd, J1 = 8.4 Hz, J2 = 2.2 Hz), 7.29 (1H, dd, J1 = 8.8 Hz, J2 = 2.5 Hz), 7.42 (1H, d, J = 2.5 Hz), 7.82 (1H, d, J = 8.5 Hz), 7.99 (1H, d, J = 2.2 Hz), 8.2 (1H, d, J = 8.8 Hz). 13C NMR (150 MHz, DMSO-d6) δ ppm: 55.9, 56.4, 103.0, 111.9, 113.6, 115.1, 116.6, 119.0, 127.3, 128.8, 146.0, 148.9, 149.1, 157.9, 165.0, 168.0, 180.3. C17H12N2O4. M.W. 308.30. Mass spectrum (EI) m/z (I, %): 308 (100).
3,9-Dibromoindolo[2,1-b]quinazolin-6,12-dione (3s). Yield 38%, mp = 350–351 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.72 (1H, dd, J1 = 8.1 Hz, J2 = 1.6 Hz), 7.84 (1H, d, J = 8.1 Hz), 7.93 (1H, dd, J1 = 8.4 Hz, J2 = 1.8 Hz), 8.22 (2H, m), 8.6 (1H, d, J = 1.7 Hz). 13C NMR (150 MHz, DMSO-d6) δ ppm: 120.2, 121.9, 122.6, 126.8, 129.3, 129.4, 130.5, 131.4, 132.6, 133.4, 146.4, 146.9, 148.1, 157.9, 181.7. C15H6Br2N2O2. M.W. 406.04. Mass spectrum (EI) m/z (I, %): 404/406/408 (95/100/95), 376/378/380 (20/30/20).
2,8-Dibromoindolo[2,1-b]quinazolin-6,12-dione (3t). Yield 25%, mp = 310–311 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.91 (1H, d, J = 8.4 Hz), 8.05 (1H, dd, J1 = 8.4 Hz, J2 = 2.0 Hz), 8.08 (1H, d, J = 2.0 Hz), 8.13 (1H, dd, J1 = 8.5 Hz, J2 = 2.3 Hz), 8.38 (1H, d, J = 8.7 Hz), 8.41 (1H, d, J = 2.4 Hz). 13C NMR (150 MHz, DMSO-d6) δ ppm: 118.9, 119.4, 123.0, 124.2, 124.7, 127.1, 129.1, 132.0, 138.2, 139.7, 144.5, 145.1, 145.5, 156.5, 180.9. C15H6Br2N2O2. M.W. 406.04. Mass spectrum (EI) m/z (I, %): 404/406/408 (95/100/95), 376/378/380 (15/20/15).
1,7-Dibromoindolo[2,1-b]quinazolin-6,12-dione (3u). Yield 21%, mp > 300 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.67 (1H, d, J = 8.2 Hz), 7.73 (1H, dd, J1 = 7.9 Hz, J2 = 7.9 Hz), 7.78 (1H, dd, J1 = 7.9 Hz, J2 = 7.9 Hz), 7.96 (2H, m), 8.52 (1H, d, J = 7.9 Hz). 13C NMR (150 MHz, DMSO-d6) δ ppm: 116.2, 119.6, 120.5, 121.0, 121.5, 130.2, 131.2, 135.4, 136.2, 138.3, 144.7, 147.6, 148.9, 155.9, 179.9. C15H6Br2N2O2. M.W. 406.04. Mass spectrum (EI) m/z (I, %): 404/406/408 (95/100/95), 376/378/380 (15/20/15).

3.1.3. General Procedure for Synthesis of Compounds 4a–u

Hydroxylamine hydrochloride (3 mmol) was added to a solution of 1 mmol of the substituted ketones (3a–u) in 6 mL of pyridine, and the mixture was refluxed for 4 h. The progress of the reaction was monitored with TLC, using chloroform–methanol mixture (10/1) as the developing solvent. The excess pyridine was removed under reduced pressure, and the residue was poured into a 0.1 M HCl solution. The precipitate was filtered off, washed with water (2 × 5 mL), and recrystallized from 1,4-dioxane.
8-Nitroindolo[2,1-b]quinazolin-6,12-dione Oxime (4a). Yield 95%, mp = 227–228 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.67 (ddd, J1 = 7.2 Hz, J2 = 7.2 Hz, J3 = 0.6 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.94 (ddd, J1 = 7.2 Hz, J2 = 7.2, J3 = 1.8 Hz, 1H), 8.33 (d, J = 7.2 Hz, 1H), 8.59 (dd, J1 = 9.0 Hz, J2 = 2.2Hz, 1H), 8.73 (d, J = 8.4Hz, 1H), 9.05 (d, J = 2.4Hz, 1H), 14.18 (s, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 117.19, 119.86, 121.81, 122.33, 127.28, 128.47, 128.76, 135.76, 143.68, 143.98, 145.57, 147.25, 148.74, 150.09, 159.18. C15H8N4O4. M.W. 308.25. Mass spectrum (EI) m/z (I, %): 308 (100), 232 (20).
8-Bromoindolo[2,1-b]quinazolin-6,12-dione Oxime (4b). Yield 90%, mp > 225 °C (dec). 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.64 (dd, J1 = 7.8 Hz, J2 = 7.8 Hz, 1H), 7.83 (d, J = 7.8 Hz, 1H), 7.88 (dd, J1 = 8.4 Hz, J2 = 2.4 Hz, 1H), 7.91 (ddd, J1 = 7.8 Hz, J2 = 7.5 Hz, J3 = 1.8 Hz, 1H), 8.30 (dd, J1 = 7.8 Hz, J2 = 1.8 Hz, 1H), 8.47 (m, 2H), 13.93 (s, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 118.60, 118.99, 121.14, 121.96, 127.07, 128.20, 128.67, 129.90, 135.03, 135.35, 138.91, 143.87, 147.45, 148.42, 158.91. C15H8BrN3O2. M.W. 342.15. Mass spectrum (EI) m/z (I, %): 343 (100), 341 (100), 313 (50), 311 (50).
8-Ethylindolo[2,1-b]quinazolin-6,12-dione Oxime (4c). Yield 95%, mp > 225 °C (dec). 1H NMR (600 MHz, DMSO-d6) δ ppm: 1.23 (s, CH3, J = 7.8 Hz, 3H), 2.72 (q, CH2, J = 7.8 Hz, 2H), 7.50 (d, J = 7.8 Hz, 1H), 7.62 (dd, J1 = 7.8 Hz, J2 = 7.8 Hz, 1H), 7.80 (d, J = 8.4 Hz, 1H), 7.83 (dd, J1 = 7.2 Hz, J2 = 7.2 Hz, 1H), 8.22 (s, 1H), 8.29 (d, J = 7.8 Hz, 1H), 8.43 (d, J = 8.4 Hz, 1H), 13.62 (s, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 16.24, 28.48, 116.59, 119.50, 122.06, 126.98, 127.09, 127.95, 128.58, 131.88, 135.08, 137.86, 142.96, 144.75, 147.48, 148.98, 158.76. C17H13N3O2. M.W. 291.30. ESI-MS: 268 (40%), 266 (100%), 238 (30%). ESI-MS: [M + H]+ Calcd for C17H13N3O2 292.1086; Found 292.1074.
8-Methoxyindolo[2,1-b]quinazolin-6,12-dione Oxime (4d). Yield 85%, mp > 225 °C (dec). 1H NMR (600 MHz, DMSO-d6) δ ppm: 3.84 (s, CH3, 3H), 7.21 (dd, J1 = 8.4 Hz, J2 = 2.4 Hz, 1H), 7.60 (ddd, J1 = 7.8 Hz, J2 = 7.8 Hz, J3 = 1.2 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.87 (m, 2H), 8.27 (dd, J1 = 7.8 Hz, J2 = 1.8 Hz, 1H), 8.42 (d, J = 9.0 Hz, 1H), 13.70 (s, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 56.17, 113.01, 117.67 (2C), 120.34, 122.06, 126.88, 127.93, 128.57, 133.44, 134.96, 144.65, 147.41, 148.92, 158.06, 158.51. ESI-MS: [M + H]+ Calcd for C16H11N3O3 294.0878; Found 294.0872.
8-Phenylindolo[2,1-b]quinazolin-6,12-dione Oxime (4e). Yield 67%, mp > 225 °C (dec). 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.43 (dd, J1 = 7.4 Hz, J2 = 7.4 Hz, 1H), 7.52 (dd, J1 = 7.5 Hz, J2 = 7.5 Hz, 2H), 7.63 (ddd, J1 = 7.5 Hz, J2 = 7.5 Hz, J3 = 1.0 Hz, 1H), 7.70 (d, J = 7.2 Hz, 2H), 7.83 (d, J = 7.7 Hz, 1H), 7.90 (ddd, J1 = 7.6 Hz, J2 = 7.6 Hz, J3 = 1.5 Hz, 1H), 7.95 (dd, J1 = 8.4 Hz, J2 = 1.9 Hz, 1H), 8.30 (dd, 1H, J1 = 7.8 Hz, J2 = 1.3 Hz), 8.59 (m, 2H), 13.72 (s, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 117.14, 120.09, 122.03, 125.75, 127.04, 127.23 (2C), 128.06, 128.33, 128.63, 129.62 (2C), 131.01, 135.21, 139.05, 139.15, 139.70, 144.65, 147.46, 148.93, 158.90. ESI-MS: [M + H]+ Calcd for C21H13N3O2 340.1086; Found 340.1090.
2-Bromo-8-nitroindolo[2,1-b]quinazolin-6,12-dione Oxime (4f). Yield 36%, mp > 225 °C (dec). 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.80 (d, J = 8.7 Hz, 1H), 8.09 (dd, J1 = 8.6 Hz, J2 = 2.4 Hz, 1H), 8.39 (d, J = 2.2 Hz, 1H), 8.59 (dd, J1 = 8.9 Hz, J2 = 2.5 Hz, 1H), 8.70 (d, J = 8.8 Hz, 1H), 9.04 (d, J = 2.4 Hz, 1H), 14.28 (s, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 117.29, 119.83, 120.98, 122.30, 123.50, 128.52, 128.68, 129.30, 130.97, 138.49, 143.66, 145.75, 146.32, 149.24, 158.07. ESI-MS: [M + H]+ Calcd for C15H7BrN4O4 386.9728; Found 386.9726.
7-Methylindolo[2,1-b]quinazolin-6,12-dione Oxime (4g). Yield 61%, mp > 225 °C (dec). 1H NMR (600 MHz, DMSO-d6) δ ppm: 3.32 (s, 3H), 7.25 (d, J1 = 7.5 Hz, 1H), 7.47 (dd, J1 = J2 = 7.8 Hz, 1H), 7.68 (ddd, J1 = J2 = 5.8 Hz, J3 = 1.5 Hz, 1H), 7.90 (m, 2H), 8.32 (dd, J1 = 7.8 Hz, J2 = 0.9 Hz, 1H), 8.39 (d, J = 8.0 Hz, 1H), 13.71 (s,1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 20.86, 114.37, 120.77, 122.18, 126.97, 128.85, 128.93, 128.99, 130.66, 135.05, 135.15, 139.48, 143.50, 144.87, 147.36, 158.66. ESI-MS: [M + H]+ Calcd for C16H11N3O2 278.0929; Found 278.0929.
9-Methylindolo[2,1-b]quinazolin-6,12-dione Oxime (4h). Yield 66%, mp > 225 °C (dec). 1H NMR (600 MHz, DMSO-d6) δ ppm: 2.47 (s, 3H), 7.26 (dd, J1 = 7.7 Hz, J2 = 1.1 Hz, 1H), 7.62 (ddd, J1 = 7.6 Hz, J2 = 7.6 Hz, J3 = 0.6 Hz, 1H), 7.81 (d, J = 7.5 Hz, 1H), 7.89 (ddd, J1 = 7.6 Hz, J2 = 7.6 Hz, J3 = 1.7 Hz, 1H), 8.24 (d, J = 7.7 Hz, 1H), 8.29 (dd, J1 = 7.8 Hz, J2 = 1.3 Hz, 1H), 8.38 (s, 1H), 13.48 (s, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 22.41, 117.02, 117.24, 122.04, 127.02, 127.66 (2C), 128.00, 128.58, 135.17, 140.06, 143.03, 144.62, 147.42, 149.12, 158.95. ESI-MS: [M + H]+ Calcd for C16H11N3O2 278.0929; Found 278.0933.
2-Trifluoromethylindolo[2,1-b]quinazolin-6,12-dione Oxime (4i). Yield 64%, mp > 225 °C (dec). 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.48 (m, 1H), 7.67 (m, 1H), 7.99 (m, 1H), 8.18 (m, 1H), 8.36 (m, 1H), 8.49 (m, 2H), 13.86 (s, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 116.82, 119.20, 122.31, 123.35, 124.21, 125.15, 127.51, 127.81, 130.00, 131.10, 132.65, 139.46, 144.67, 150.08, 150.98, 158.33. 19F NMR (376 MHz, DMSO) δ ppm: −60.88 (s). 19F NMR (1H-decoupled) (376 MHz, DMSO) δ ppm: −60.88 (s). ESI-MS: [M + H]+ Calcd for C16H8F3N3O2 332.0646; Found 332.0648.
2-Bromoindolo[2,1-b]quinazolin-6,12-dione Oxime (4j). Yield 43%, mp > 225 °C (dec). 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.46 (dd, J1 = 7.5 Hz, J2 = 7.5 Hz, 1H), 7.66 (dd, J1 = 7.5 Hz, J2 = 7.5 Hz, 1H), 7.75 (d, J = 8.7 Hz, 1H), 8.02 (dd, J1 = 8.6 Hz, J2 = 2.3 Hz, 1H), 8.34 (d, J = 2.4 Hz, 1H), 8.37 (d, J = 7.6 Hz, 1H), 8.50 (d, J = 8.0 Hz, 1H), 13.72 (s, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 116.78, 119.31, 120.49, 123.72, 127.38, 127.85, 129.08, 130.82, 132.60, 137.90, 139.53, 144.62, 146.52, 149.31, 157.83. ESI-MS: [M + H]+ Calcd for C15H8BrN3O2 341.9878; Found 341.9877.
3-Bromoindolo[2,1-b]quinazolin-6,12-dione Oxime (4k). Yield 60%, mp > 225 °C (dec). 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.47 (dd, J1 = 7.6 Hz, J2 = 7.6 Hz, 1H), 7.66 (dd, J1 = 7.9 Hz, J2 = 7.9 Hz, 1H), 7.78 (dd, J1 = 8.4 Hz, J2 = 1.7 Hz, 1H), 8.02 (s, 1H), 8.19 (d, J = 8.5 Hz, 1H), 8.37 (d, J = 7.5 Hz, 1H), 8.52 (d, J = 8.1 Hz, 1H), 13.75 (s, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 116.76, 119.25, 121.27, 127.33, 127.83, 128.63, 128.96, 130.74, 130.88, 132.63, 139.64, 144.65, 148.69, 150.12, 158.57. ESI-MS: [M + H]+ Calcd for C15H8BrN3O2 341.9878; Found 341.9940.
3-Fluoroindolo[2,1-b]quinazolin-6,12-dione Oxime (4l). Yield 76%, mp > 225 °C (dec). 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.46 (m, 2H), 7.60 (dd, J1 = 9.8 Hz, J2 = 2.1 Hz, 1H), 7.65 (dd, J1 = 7.8 Hz, J2 = 7.8 Hz, 1H), 8.32 (dd, J1 = 8.7 Hz, J2 = 7.5 Hz, 1H), 8.35 (d, J = 7.7 Hz, 1H), 8.49 (d, J = 8.1 Hz, 1H), 13.72 (s, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 113.87, 116.37, 116.72, 119.17, 127.23, 127.81, 129.95, 132.57, 139.64, 144.64, 149.67, 150.16, 158.30, 165.37, 167.04. 19F NMR (376 MHz, DMSO) δ ppm: −104.09 (m). 19F NMR (1H-decoupled) (376 MHz, DMSO) δ ppm: −104.10 (s). ESI-MS: [M + H]+ Calcd for C15H8FN3O2 282.0678; Found 282.0681.
3-Nitroindolo[2,1-b]quinazolin-6,12-dione Oxime (4m). Yield 70%, mp > 225 °C (dec). 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.50 (dd, J1 = 7.3 Hz, J2 = 7.3 Hz, 1H), 7.70 (ddd, J1 = 8.0 Hz, J2 = 8.0 Hz, J3 = 1.2 Hz, 1H), 8.33 (dd, J1 = 8.8 Hz, J2 = 2.2 Hz, 1H), 8.39 (d, J = 7.7 Hz, 1H), 8.52 (m, 3H), 13.89 (s, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 116.91, 119.28, 121.42, 123.38, 126.53, 127.68, 127.82, 129.15, 132.71, 139.45, 144.54, 147.99, 150.89, 151.65, 158.05. ESI-MS: [M + H]+ Calcd for C15H8N4O4 309.0623; Found 309.0625.
2-Nitroindolo[2,1-b]quinazolin-6,12-dione Oxime (4n): Yield 55%, mp > 225 °C (dec). 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.47 (ddd, J1 = 9.0 Hz, J2 = 8.0 Hz, J3 = 0.9 Hz, 1H), 7.66 (ddd, J1 = 9.0 Hz, J2 = 8.0 Hz, J3 = 1.3 Hz, 1H), 7.96 (d, J = 9.0 Hz, 1H), 8.34 (d, J = 7.2 Hz, 1H), 8.47 (d, J = 7.8 Hz, 1H), 8.57 (dd, J1 = 7.2 Hz, J2 = 2.4 Hz, 1H), 8.89 (d, J = 6.0 Hz 1H), 13.97 (s, 1H). 13C NMR (150 MHz, DMSO-d6) δ ppm: 116.83, 119.09, 122.27, 122.75, 127.67, 127.74, 128.94, 130.19, 132.66, 139.21, 144.62, 145.73, 151.68, 151.80, 158.09. ESI-MS: [M + H]+ Calcd for C15H8N4O4 309.0623; Found 309.0622.
2,8-Dimethylindolo[2,1-b]quinazolin-6,12-dione Oxime (4o). Yield 58%, mp > 300 °C (dec). 1H NMR (600 MHz, DMSO-d6) δ ppm: 2.60 (s, 3H); 2.90 (s, 3H); 7.25 (d, J = 7.7 Hz, 1H); 7.43 (d, J = 7.7 Hz, 1H); 7.46 (dd, J1 = J2 = 7.9 Hz, 1H); 7.695 (d, J = 7.9 Hz, 1H); 7.74 (dd, J1 = J2 = 7.7 Hz, 1H); 8.40 (d, J = 8.0 Hz, 1H); 13.67 (s, 1H). 13C NMR (600 MHz, DMSO-d6) δ ppm: 66.8, 114.5, 120.5, 120.7, 127.3, 128.8, 130.7, 131.5, 134.2, 135.0, 139.7, 141.4, 143.4, 144.9, 148.9, 159.5. ESI-MS: [M + H]+ Calcd for C17H13N3O2 292.1086; Found 292.1086.
1,7-Dimethylindolo[2,1-b]quinazolin-6,12-dione Oxime (4p). Yield 59%, mp = 190–191 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 2.60 (s, 3H); 2.90 (s, 3H); 7.25 (d, J = 7.7 Hz, 1H); 7.43 (d, J = 7.7 Hz, 1H); 7.46 (dd, J1 = J2 = 7.9 Hz, 1H); 7.695 (d, J = 7.9 Hz, 1H); 7.74 (dd, J1 = J2 = 7.7 Hz, 1H); 8.40 (d, J = 8.0 Hz, 1H);13.67 (s, 1H). 13C NMR (600 MHz, DMSO-d6) δ ppm: 66.8, 114.5, 120.5, 120.7, 127.3, 128.8, 130.7, 131.5, 134.2, 135.0, 139.7, 141.4, 143.4, 144.9, 148.9, 159.5. ESI-MS: [M + H]+ Calcd for C17H13N3O2 292.1086; Found 292.1088.
2,8-Dimethoxylindolo[2,1-b]quinazolin-6,12-dione Oxime (4q). Yield 85%, mp = 262–263 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 3.844 (s, 1H); 3.9 (s, 1H); 7.22 (dd, J1 = 2.7 Hz, J2 = 8.8 Hz, 1H); 7.465 (dd, J1 = 2.9 Hz, J2 = 8.8 Hz, 1H); 7.650 (d, J = 2.9 Hz, 1H); 7.743 (d, J = 8.8 Hz, 1H); 7.890 (d, J = 2.7 Hz, 1H); 8.430 (d, J = 8.8 Hz, 1H); 13.6 (s, 1H). 13C NMR (DMSO-d6) δ ppm: 56.2, 107.5, 113.1, 117.7, 120.5, 123.0, 124.0, 130.3, 133.4, 141.7, 144.5, 146.8, 158.1, 158.2, 159.0. ESI-MS: [M + H]+ Calcd for C17H13N3O4 324.0984; Found 324.0922.
3,9-Dimethoxylindolo[2,1-b]quinazolin-6,12-dione Oxime (4r). Yield 30%, mp = 292–293 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 3.90 (s, 3H); 3.935 (s, 3H); 6.98 (dd, J1 = 2.4 Hz, J2 = 8.8 Hz, 1H); 7.190 (dd, J1 = 2.5 Hz, J2 = 8.7 Hz, 1H); 7.268 (d, J = 2.5 Hz, 1H); 8.093 (d, J = 2.4 Hz, 1H); 8.165 (d, J = 8.8 Hz, 1H); 8.257 (d, J = 8.7 Hz, 1H); 13.287 (s, 1H). 13C NMR (600 MHz, DMSO-d6) δ ppm: 56.3, 56.4, 103.0, 110.2, 112.0, 112.5, 115.2, 117.2, 128.6, 129.2, 141.6, 144.2, 149.7, 150.0, 158.7, 162.4, 164.8. ESI-MS: [M + H]+ Calcd for C17H13N3O4 324.0984; Found 324.0983.
3,9-Dibromoindolo[2,1-b]quinazolin-6,12-dione Oxime (4s). Yield 40%, mp > 300 °C (dec). 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.68 (dd, J1 = 2.0 Hz, J2 = 8.4 Hz, 1H); 7.79 (dd, J1 = 2.0 Hz, J2 = 8.4 Hz, 1H); 8.034 (d, J = 1.8 Hz, 1H); 8.185 (d, J = 8.4 Hz, 1H); 8.27 (d, J = 8.4 Hz, 1H); 8.645 (d, J = 1.8 Hz, 1H); 13.91 (s, 1H). 13C NMR (600 MHz, DMSO-d6) δ ppm: 118.4, 119.4, 121.0, 125.1, 128.7, 129.0, 129.2, 129.4, 130.1, 130.8, 131.1, 140.5, 144.1, 148.6, 158.6. ESI-MS: [M − H]− Calcd for C15H7Br2N3O2 417.8826; Found 417.8880.
2,8-Dibromoindolo[2,1-b]quinazolin-6,12-dione Oxime (4t). Yield 56%, mp = 250–251 °C. 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.773 (d, J = 8.6 Hz, 1H); 7.883 (dd, J1 = 2.1 Hz, J2 = 8.6 Hz, 1H); 8.055 (dd, J1 = 2.4 Hz, J2 = 8.7 Hz, 1H); 8.36 (d, J = 2.4 Hz, 1H); 8.45 (d, J = 8.7 Hz, 1H); 8.475 (d, J = 2.1 Hz, 1H); 14.022 (s, 1H). 13C NMR (DMSO-d6) δ ppm: 118.6, 119.3, 120.7, 121.1, 123.6, 129.1, 129.8, 130.1, 135.1, 138.1, 138.6, 143.8, 146.5, 148.9, 157.8. ESI-MS: [M − H]− Calcd for C15H7Br2N3O2 417.8826; Found 417.8833.
1,7-Dibromoindolo[2,1-b]quinazolin-6,12-dione Oxime (4u). Yield 21%, mp > 300 °C (dec). 1H NMR (600 MHz, DMSO-d6) δ ppm: 7.495 (dd, J1 = J2 = 8.0 Hz, 1H); 7.665 (dd, J1 = 0.7 Hz, J2 = 8.0 Hz, 1H); 7.735 (dd, J1 = J2 = 8.0 Hz, 1H); 7.860 (dd, J1 = 1.1 Hz; J2 = 8.0 Hz, 1H); 7.895 (dd, J1 = 1.1 Hz; J2 = 8.0 Hz, 1H); 8.575 (d, J = 0.7 Hz, 1H); 14.03 (s, 1H). 13C NMR (600 MHz, DMSO-d6) δ ppm: 115.5, 116.1, 119.9, 121.4, 121.8, 129.4, 131.6, 132.0, 135.2, 135.3, 141.0, 142.7, 143.1, 150.0, 157.0. ESI-MS: [M − H]− Calcd for C15H7Br2N3O2 417.8826; Found 417.8957.

3.1.4. General Procedure for Synthesis of Compounds 5a,b

A solution of monochloroacetic acid ethyl ester for 5a (1.5 mmol in 5 mL of DMSO) or bromomalonic acid diethyl ester for 5b (1.5 mmol in 5 mL of DMSO) was added to a suspension of TRYP-Ox (1.0 mmol) and KOH (2.0 mmol) in 5 mL of DMSO. The mixtures were stirred for 1 h at room temperature and added to 150 mL of water. The precipitates were filtered off and recrystallized from EtOH to obtain 5a (69% yield) and 5b (33% yield), respectively.
Ethyl 2-(((12-Oxoindolo[2,1-b]quinazolin-6(12H)-ylidene)amino)oxy)acetate (5a). Yield 69%, colorless crystals, mp = 218 °C. 1H NMR (400 MHz, CDCl3), δ, ppm: 1.34 (t, 3H, J = 6 Hz, CH3), 4.30 (q, 2H, J = 6 Hz, CH2CH3), 5.16 (s, 2H, =N-O-CH2), 7.40 (td, 1H, J1 = 1 Hz, J2 = 7.7 Hz), 7.56–7.65 (m, 2H), 7.81 (td, 1H, J1 = 1.6 Hz, J2 = 7.7 Hz), 7.97 (d, 1H, J = 8 Hz), 8.42 (m, 2H), 8.65 (d, 1H, J = 8 Hz). 13C NMR (100 MHz, CDCl3), δ, ppm: 14.35, 61.59, 73.22, 117.29, 118.93, 122.34, 127.14, 127.31, 128.34, 129.09, 133.63, 134.88, 140.47, 146.39, 147.11, 147.89, 159.15, 168.62. IR band, cm−1: 1686 (C=N), 963 (N-O), 1745 (C=O). Found, %: C 65.58, H 4.19, N 12.13. C19H15N3O4. Calculated, %: C 65.32, H 4.33, N 12.03.
Diethyl 2-(((12-Oxoindolo[2,1-b]quinazolin-6(12H)-ylidene)amino)oxy)malonate (5b). Yield 33%, colorless crystals, mp = 211 °C. 1H NMR (400 MHz, CDCl3), d, ppm: 1.34 (t, 6H, J = 7 Hz, CH3), 4.31 (q, 4H, J = 7 Hz, CH2CH3), 5.17 (s, 1H, =N-O-CH), 7.42 (td, 1H, J1 = 1 Hz, J2 = 7.7 Hz), 7.58-7.67 (m, 2H), 7.82 (td, 1H, J1 = 1.6 Hz, J2 = 6 Hz), 7.98 (d, 1H, J = 8 Hz), 8.44 (m, 2H), 8.68 (d, 1H, J = 8 Hz). 13C NMR (100 MHz, CDCl3), δ, ppm: 14.35, 61.58, 73.20, 117.29, 118.93, 122.33, 127.13, 127.31, 128.33, 129.05, 129.09, 133.62, 134.87, 140.47, 146.39, 147.11, 147.89, 159.14, 168.61. IR band, cm−1: 1687 (C=N), 964 (N-O), 1746 (C=O). Found, %: C 62.97, H 4.32, N 10.18. C22H19N3O6. Calculated, %: C 62.70, H 4.54, N 9.97.

3.1.5. General Procedure for Synthesis of Compounds 5c,d

TRYP-Ox (0.5 mmol) was dissolved at 0 °C in 6 mL of pyridine, chloroformate (0.5 mmol) was added, the mixture was stirred for 5 min, and precipitated in water. The precipitate that formed was filtered off, and the final compounds 5c and 5d were recrystallized from methanol.
6-(((Methoxycarbonyl)oxy)imino)indolo[2,1-b]quinazolin-12(6H)-one (5c). Yield 96%, mp = 197 °C. 1H NMR (400 Hz, acetone-d6), d, ppm: 3.77 (s, (3·0.67)H, CH3), 7.55 (td, 1H, J1 = 2.6 Hz, J2 = 7.8 Hz), 7.72 (td, 1H, J1 = 2 Hz, J2 = 7.8 Hz), 7.83 (td, 1H, J1 = 1.6 Hz, J2 = 8 Hz), 7.89–7.97 (m, 2H), 8.39 (dd, 2H, J1 = 1.6 Hz, J2 = 8 Hz), 8.67 (d, 1H, J = 8 Hz); the spectrum shows signals of the second geometric isomer at 4.07 (s, (3·0.33)H, CH3). IR band, cm−1: 1649 (C=N), 922 (N-O), 1749 (C=O); 1879 (-COOCH3). Found, %: C 63.63, H 3.35, N 12.92 C17H11N3O4. Calculated, %: C 63.55, H 3.45, N 13.08. LC/MS (ESI+)—m/z: 322.0820 experimental ([C17H11N3O4 + H]+ = 322.0822 theor.); m/z: 344.0642 exp. ([C17H11N3O4 + Na]+ = 344.0642 theor.); exit time 72–120 s.
6-((((Prop-2-yn-1-yloxy)carbonyl)oxy)imino)indolo[2,1-b]quinazolin-12(6H)-one (5d). Yield 38%, mp 210 °C. 1H NMR (400 Hz, CDCl3), d, ppm: 2.64 (t, 1H, J = 2.4 Hz, C≡CH), 5.00 (d, 2H, J = 2.4 Hz, CH2-C≡CH), 7.44 (td, 1H, J1 = 1.2 Hz, J2 = 7.8 Hz), 7.62 (td, 1H, J1 = 1.2 Hz, J2 = 7.8 Hz), 7.70 (td, 1H, J1 = 1.5 Hz, J2 = 7.9 Hz), 7.83 (td, 1H, J1 = 1.4 Hz, J2 = 7.9 Hz), 7.98 (d, 1H, J = 7 Hz), 8.39–8.44 (m, 2H), 8.65 (d, 1H, J = 8 Hz). IR band, cm−1: 1690 (C=N), 970 (N-O), 1791 (C=O). Found, %: C 66.37, H 3.12, N 12.36. C19H11N3O4. Calculated, %: C 66.09, H 3.21, N 12.17. LC/MS (ESI+)—m/z: 346.0820 experimental ([C19H11N3O4 + H]+ = 346.0822 theor.); m/z: 368.0642 exp. ([C19H11N3O4 + Na]+ = 368.0642 theor.); exit time 72–120 s.

3.1.6. Preparation of 6-(((Benzo[d][1,3]dioxol-5-carbonyl)oxy)imino)indolo[2,1-b]quinazolin-12(6H)-one (5e)

Piperonyl chloride (4c) (0.0923 g, 0.5 mmol) was added to TRYP-Ox (0.132 g, 0.5 mmol) dissolved at 0 °C in 6 mL of pyridine, and the mixture was stirred for 60 min and precipitated in water. The resulting precipitate was dissolved in boiling methylene chloride and cooled to −40 °C. The precipitate formed from the solution was filtered on a chilled filter and washed with chilled methylene chloride. Yield 41%, mp 206–208 °C. 1H NMR (400 Hz, CDCl3), d, ppm: 6.15 (s, 2H, CH2), 6.98 (d, 1H, J = 8 Hz), 7.47 (td, 1H, J1 = 1.2 Hz, J2 = 7.6 Hz), 7.61–7.66 (m, 2H), 7.71 (td, 1H, J1 = 1.2 Hz, J2 = 8 Hz), 7.83-7.87 (m, 2H), 8.00 (d, 1H, J = 8 Hz), 8.35 (d, 1H, J = 8 Hz), 8.44 (dd, 1H, J = 1.6 Hz, J = 7.6 Hz), 8.71 (d, 1H, J = 8 Hz). IR band, cm−1: 1686 (C=N), 967 (N-O), 1754 (C=O); 1855 (-COOC-) Found, %: C 67.33, H 3.04, N 10.50. C23H13N3O5 Calculated, %: C 67.15, H 3.19, N 10.21. LC/MS (ESI+)—m/z: 412.0932 experimental ([C23H13N3O5 + H]+ = 412.0928 theor.); m/z: 434.0751 exp. ([C23H13N3O5 + Na]+ = 434.0747 theor.); exit time 72–120 s.

3.2. Biological Analysis

3.2.1. Kinase Kd Determination

Compounds were submitted for dissociation constant (Kd) determination using KINOMEscan (Eurofins Pharma Discovery, San Diego, CA, USA), as described previously [58]. Briefly, kinases were produced and displayed on T7 phages or expressed in HEK-293 cells. Binding reactions were performed at room temperature for 1 h, and the fraction of kinase not bound to the test compound was determined by capture with an immobilized affinity ligand and quantified by quantitative polymerase chain reaction. Primary screening at fixed concentrations of compounds was performed in duplicate. To determine dissociation constant Kd, a 12-point half-log dilution series (a maximum concentration of 33 μM) was used. Assays were performed in duplicate, and their average mean value is displayed.

3.2.2. Cell Culture

All cells were cultured at 37 °C in a humidified atmosphere containing 5% CO2. Human THP-1Blue monocytic cells obtained from InvivoGen (San Diego, CA, USA) were cultured in RPMI 1640 medium (Mediatech Inc., Herndon, VA, USA) supplemented with 10% (v/v) fetal bovine serum (FBS), 4.5 g/L glucose, 100 μg/mL streptomycin, 100 U/mL penicillin, 100 μg/mL phleomycin (Zeocin), and 10 μg/mL blasticidin S. Human monocyte-macrophage MonoMac-6 cells (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) were grown in RPMI 1640 medium supplemented with 10% (v/v) FBS, 10 μg/mL bovine insulin, 100 μg/mL streptomycin, and 100 U/mL penicillin.

3.2.3. Analysis of AP-1/NF-κB Activation

Activation of AP-1/NF-κB was measured using an alkaline phosphatase reporter gene assay in THP1-Blue cells. Human monocytic THP-1Blue cells were stably transfected with a secreted embryonic alkaline phosphatase gene that was under the control of a promoter inducible by AP-1/NF-κB. THP-1Blue cells (2 × 105 cells/well) were pretreated with the test compound or DMSO (1% final concentration) for 30 min, followed by addition of 250 ng/mL LPS (from Escherichia coli K-235; Sigma Chemical Co., St. Louis, MO, USA) for 24 h, and alkaline phosphatase activity was measured in cell supernatants using QUANTI-Blue mix (InvivoGen) with absorbance at 655 nm and compared with positive control samples (LPS). The concentrations of compound that caused 50% inhibition of the AP-1/NF-κB reporter activity (IC50) were calculated.

3.2.4. Cytotoxicity Assay

Cytotoxicity was analyzed with a CellTiter-Glo Luminescent Cell Viability Assay Kit from Promega (Madison, WI, USA), according to the manufacturer’s protocol. Cells were treated with the compound under investigation and cultivated for 24 h. After treatment, the cells were allowed to equilibrate to room temperature for 30 min, substrate was added, and the luminescence measured using a Fluoroscan Ascent FL (Thermo Fisher Scientific, Waltham, MA, USA). The cell IC50 values were calculated by plotting the percentage inhibition against the logarithm of inhibitor concentration (at least five points).

3.2.5. Analysis of c-Jun Phosphorylation

MonoMac-6 cell lysates were prepared using Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA, USA). The phospho-c-Jun content was measured with ELISA using the PathScan Phospho-c-Jun (Ser63) Sandwich ELISA Kit II (Cell Signaling Technology, USA), and the data are shown as the ratio of phospho-c-Jun vs. total c-Jun, which was measured using the FastScanTM Total c-Jun ELISA kit (Cell Signaling Technology).

3.3. Molecular Docking

The geometry of JNK3 was obtained by downloading its crystal structure from the Protein Data Bank (PDB entry code 1PMV) into Molegro 6.0 software (Molegro ApS, Aarhus, Denmark). All of the solvent molecules were removed, and the search space was chosen to be a sphere centered on the co-crystallized ligand present in the corresponding PDB structure. The radius of the sphere was 10 Å, which completely encompassed the co-crystallized ligand and the JNK3 binding site. Side chains of all JNK amino acid residues within the corresponding sphere were regarded as flexible during docking. The number of such residues was 39. The flexible residues were treated with the default settings of the “Setup Sidechain Flexibility” tool in Molegro, and a softening parameter of 0.7 was applied during flexible docking, according to the standard protocol using the Molegro Virtual Docker 6.0 (MVD). Before docking, structures of compounds were pre-optimized using HyperChem 7 software (HyperCube, Gainesville, FL, USA) with the MM+ force field, and saved in the Tripos MOL2 format (Tripos, St. Louis, MO, USA). The ligand structures were imported into MVD. The options “Create explicit hydrogens”, “Assign charges (calculated by MVD)”, and “Detect flexible torsions in ligands” were enabled during importing. Appropriate protonation states of the ligands were also automatically generated at this step. Each ligand was subjected to 30 docking runs with respect to the JNK3 structure using MVD software. The docking pose with the lowest MolDock docking score [69] was selected for each ligand and analyzed using the built-in tools of MVD.

3.4. DFT Calculations

ORCA 5.0 computational chemistry software [70] was used for density functional theory (DFT) calculations of compound 4d. Geometry optimizations were performed using the M06-2X functional [65] with the 6-311++G(2d,2p) basis set. Normal vibration analysis was performed for the optimized geometries to establish the nature of the stationary points (i.e., minimum or transition state). Transition state (TS) geometry was obtained using the climbing image nudged elastic band (CI-NEB) approach [71] with the PBEh-3c composite method [72] followed by TS optimization at the M06-2X/6-311++G(2d,2p) level of theory. During CI-NEB calculations, eight intermediate images on the isomerization path were used. All calculations were performed using the conductor-like polarizable continuum solvation model (CPCM) [73] with DMSO as the solvent.

4. Conclusions

Based on a tryptanthrin scaffold, we designed and synthesized a series of substituted TRYP-Ox derivatives in an effort to obtain novel JNK3-selective inhibitors. As determined in our JNK1-3 binding assays, we were successful in identifying at least two highly selective JNK3 inhibitors. These compounds inhibited LPS-induced NF-κB/AP-1 transcription activity in THP-1Blue cells and IL-6 production in MonoMac-6 monocytic cells in the low micromolar range. In addition, the JNK3-selective inhibitors 4d and 4e decreased LPS-induced c-Jun phosphorylation in MonoMac-6 cells, directly confirming JNK inhibition. Molecular docking confirmed the binding interaction of the active compounds in the JNK3 catalytic site. These compounds may be useful for investigating the role of JNK3 in various models of pathologies such as Alzheimer’s disease, Parkinson’s disease, and cancer.

Author Contributions

Conceptualization, I.A.S., O.S.K., A.I.K. and M.T.Q.; methodology, I.A.S., O.S.K., L.N.K. and A.I.K.; formal analysis, I.A.S., O.S.K., L.N.K. and A.I.K.; investigation, I.A.S., O.S.K., A.R.K., L.N.K., A.I.K., S.I.C., A.V.R. and M.O.S.; resources, O.S.K., A.I.K. and M.T.Q.; writing—original draft preparation, I.A.S., O.S.K., A.R.K. and A.I.K.; writing—review and editing, I.A.S., O.S.K., A.R.K., A.I.K. and M.T.Q.; supervision, O.S.K., A.I.K. and M.T.Q.; funding acquisition, O.S.K., A.I.K. and M.T.Q. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported in part by National Institutes of Health IDeA Program Grant GM103474; USDA National Institute of Food and Agriculture Hatch project 1009546; the Montana State University Agricultural Experiment Station; the Ministry of Science and Higher Education of the Russian Federation (project no. FSWW-2023-0008), and the Tomsk Polytechnic University Development Program.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the article.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Sample Availability

Samples of synthesized compounds are available from the authors.

References

  1. Kyriakis, J.M.; Banerjee, P.; Nikolakaki, E.; Dai, T.; Rubie, E.A.; Ahmad, M.F.; Avruch, J.; Woodgett, J.R. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994, 369, 156–160. [Google Scholar] [CrossRef] [PubMed]
  2. Abdelrahman, K.S.; Hassan, H.A.; Abdel-Aziz, S.A.; Marzouk, A.A.; Narumi, A.; Konno, H.; Abdel-Aziz, M. JNK signaling as a target for anticancer therapy. Pharmacol. Rep. 2021, 73, 405–434. [Google Scholar] [CrossRef] [PubMed]
  3. Johnson, G.L.; Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298, 1911–1912. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Lowes, V.L.; Ip, N.Y.; Wong, Y.H. Integration of signals from receptor tyrosine kinases and G protein-coupled receptors. Neurosignals 2002, 11, 5–19. [Google Scholar] [CrossRef]
  5. Hammouda, M.B.; Ford, A.E.; Liu, Y.; Zhang, J.Y. The JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer. Cells 2020, 9, 857. [Google Scholar] [CrossRef] [Green Version]
  6. Ip, Y.T.; Davis, R.J. Signal transduction by the c-Jun N-terminal kinase (JNK)—From inflammation to development. Curr. Opin. Cell Biol. 1998, 10, 205–219. [Google Scholar] [CrossRef]
  7. Javadov, S.; Jang, S.; Agostini, B. Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: Therapeutic perspectives. Pharmacol. Ther. 2014, 144, 202–225. [Google Scholar] [CrossRef] [Green Version]
  8. Nijboer, C.H.; van der Kooij, M.A.; van Bel, F.; Ohl, F.; Heijnen, C.J.; Kavelaars, A. Inhibition of the JNK/AP-1 pathway reduces neuronal death and improves behavioral outcome after neonatal hypoxic-ischemic brain injury. Brain Behav. Immun. 2010, 24, 812–821. [Google Scholar] [CrossRef]
  9. Geng, C.; Wei, J.; Wu, C. Mammalian STE20-like kinase 1 knockdown attenuates tnfalpha-mediated neurodegenerative disease by repressing the JNK pathway and mitochondrial stress. Neurochem. Res. 2019, 44, 1653–1664. [Google Scholar] [CrossRef]
  10. Johnson, G.L.; Nakamura, K. The c-jun kinase/stress-activated pathway: Regulation, function and role in human disease. Biochim. Biophys. Acta 2007, 1773, 1341–1348. [Google Scholar] [CrossRef] [Green Version]
  11. Waetzig, V.; Herdegen, T. Context-specific inhibition of JNKs: Overcoming the dilemma of protection and damage. Trends Pharmacol. Sci. 2005, 26, 455–461. [Google Scholar] [CrossRef] [PubMed]
  12. Guma, M.; Ronacher, L.M.; Firestein, G.S.; Karin, M.; Corr, M. JNK-1 deficiency limits macrophage-mediated antigen-induced arthritis. Arthritis Rheum. 2011, 63, 1603–1612. [Google Scholar] [CrossRef]
  13. Bogoyevitch, M.A.; Boehm, I.; Oakley, A.; Ketterman, A.J.; Barr, R.K. Targeting the JNK MAPK cascade for inhibition: Basic science and therapeutic potential. Biochim. Biophys. Acta 2004, 1697, 89–101. [Google Scholar] [CrossRef] [PubMed]
  14. Zhang, G.Y.; Zhang, Q.G. Agents targeting c-Jun N-terminal kinase pathway as potential neuroprotectants. Expert Opin. Investig. Drugs 2005, 14, 1373–1383. [Google Scholar] [CrossRef] [PubMed]
  15. Ge, H.X.; Zou, F.M.; Li, Y.; Liu, A.M.; Tu, M. JNK pathway in osteoarthritis: Pathological and therapeutic aspects. J. Recept. Sig. Transd. 2017, 37, 431–436. [Google Scholar] [CrossRef] [PubMed]
  16. Solinas, G.; Becattini, B. JNK at the crossroad of obesity, insulin resistance, and cell stress response. Mol. Metab. 2017, 6, 174–184. [Google Scholar] [CrossRef] [PubMed]
  17. Kumar, A.; Singh, U.K.; Kini, S.G.; Garg, V.; Agrawal, S.; Tomar, P.K.; Pathak, P.; Chaudhary, A.; Gupta, P.; Malik, A. JNK pathway signaling: A novel and smarter therapeutic targets for various biological diseases. Future Med. Chem. 2015, 7, 2065–2086. [Google Scholar] [CrossRef]
  18. Wu, Q.H.; Wu, W.D.; Jacevic, V.; Franca, T.C.C.; Wang, X.; Kuca, K. Selective inhibitors for JNK signalling: A potential targeted therapy in cancer. J. Enzym. Inhib. Med. Chem. 2020, 35, 574–583. [Google Scholar] [CrossRef] [Green Version]
  19. Plotnikov, M.B.; Aliev, O.I.; Shamanaev, A.Y.; Sidekhmenova, A.V.; Anishchenko, A.M.; Fomina, T.I.; Rydchenko, V.S.; Khlebnikov, A.I.; Anfinogenova, Y.J.; Schepetkin, I.A.; et al. Antihypertensive activity of a new c-Jun N-terminal kinase inhibitor in spontaneously hypertensive rats. Hypertens. Res. 2020, 43, 1068–1078. [Google Scholar] [CrossRef]
  20. Plotnikov, M.B.; Chernysheva, G.A.; Aliev, O.I.; Smol’iakova, V.I.; Fomina, T.I.; Osipenko, A.N.; Rydchenko, V.S.; Anfinogenova, Y.J.; Khlebnikov, A.I.; Schepetkin, I.A.; et al. Protective effects of a new c-Jun N-terminal kinase inhibitor in the model of global cerebral ischemia in rats. Molecules 2019, 24, 1722. [Google Scholar] [CrossRef] [Green Version]
  21. Plotnikov, M.B.; Chernysheva, G.A.; Smolyakova, V.I.; Aliev, O.I.; Trofimova, E.S.; Sherstoboev, E.Y.; Osipenko, A.N.; Khlebnikov, A.I.; Anfinogenova, Y.J.; Schepetkin, I.A.; et al. Neuroprotective effects of a novel inhibitor of c-Jun N-terminal kinase in the rat model of transient focal cerebral ischemia. Cells 2020, 9, 1860. [Google Scholar] [CrossRef]
  22. Cho, H.; Hah, J.M. A Perspective on the development of c-Jun N-terminal kinase inhibitors as therapeutics for Alzheimer’s Disease: Investigating Structure through Docking Studies. Biomedicines 2021, 9, 1431. [Google Scholar] [CrossRef] [PubMed]
  23. Gehringer, M.; Muth, F.; Koch, P.; Laufer, S.A. c-Jun N-terminal kinase inhibitors: A patent review (2010–2014). Expert Opin. Ther. Pat. 2015, 25, 849–872. [Google Scholar] [CrossRef] [PubMed]
  24. Rehfeldt, S.C.H.; Majolo, F.; Goettert, M.I.; Laufer, S. c-Jun N-terminal kinase inhibitors as potential leads for new therapeutics for Alzheimer’s Diseases. Int. J. Mol. Sci. 2020, 21, 9677. [Google Scholar] [CrossRef] [PubMed]
  25. Ha, J.; Kang, E.; Seo, J.; Cho, S. Phosphorylation Dynamics of JNK signaling: Effects of dual-specificity phosphatases (DUSPs) on the JNK pathway. Int. J. Mol. Sci. 2019, 20, 6157. [Google Scholar] [CrossRef] [Green Version]
  26. Bode, A.M.; Dong, Z. The functional contrariety of JNK. Mol. Carcinog. 2007, 46, 591–598. [Google Scholar] [CrossRef] [Green Version]
  27. Gupta, S.; Barrett, T.; Whitmarsh, A.J.; Cavanagh, J.; Sluss, H.K.; Derijard, B.; Davis, R.J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 1996, 15, 2760–2770. [Google Scholar] [CrossRef] [Green Version]
  28. Abdelli, S.; Bonny, C. JNK3 Maintains expression of the insulin receptor substrate 2 (IRS2) in insulin-secreting cells: Functional consequences for insulin signaling. PLoS ONE 2012, 7, 35997. [Google Scholar] [CrossRef] [Green Version]
  29. Zhou, Y.; Zhang, P.X.; Zheng, X.Y.; Ye, C.T.; Li, M.Y.; Bian, P.Y.; Fan, C.; Zhang, Y. miR-155 regulates pro- and anti-inflammatory cytokine expression in human monocytes during chronic hepatitis C virus infection. Ann. Transl. Med. 2021, 9, 1618. [Google Scholar] [CrossRef]
  30. Gorogh, T.; Beress, L.; Quabius, E.S.; Ambrosch, P.; Hoffmann, M. Head and neck cancer cells and xenografts are very sensitive to palytoxin: Decrease of c-jun n-terminale kinase-3 expression enhances palytoxin toxicity. Mol. Cancer 2013, 12, 12. [Google Scholar] [CrossRef] [Green Version]
  31. Lapouge, G.; Millon, R.; Muller, D.; Abecassis, J.; Eber, M.; Bergerat, J.P.; Klein-Soyer, C. Cisplatin-induced genes as potential markers for thyroid cancer. Cell. Mol. Life Sci. 2005, 62, 53–64. [Google Scholar] [CrossRef] [PubMed]
  32. Pi, X.; Wu, Y.; Ferguson, J.E., 3rd; Portbury, A.L.; Patterson, C. SDF-1α stimulates JNK3 activity via eNOS-dependent nitrosylation of MKP7 to enhance endothelial migration. Proc. Natl. Acad. Sci. USA 2009, 106, 5675–5680. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Lattin, J.E.; Greenwood, K.P.; Daly, N.L.; Kelly, G.; Zidar, D.A.; Clark, R.J.; Thomas, W.G.; Kellie, S.; Craik, D.J.; Hume, D.A.; et al. Beta-arrestin 2 is required for complement C1q expression in macrophages and constrains factor-independent survival. Mol. Immunol. 2009, 47, 340–347. [Google Scholar] [CrossRef]
  34. Ebelt, N.D.; Cantrell, M.A.; van den Berg, C.L. c-Jun N-terminal kinases mediate a wide range of targets in the metastatic cascade. Genes Cancer 2013, 4, 378–387. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Yang, X.; Xiang, X.; Xia, M.; Su, J.; Wu, Y.; Shen, L.; Xu, Y.; Sun, L. Inhibition of JNK3 promotes apoptosis induced by BH3 mimetic S1 in chemoresistant human ovarian cancer cells. Anat. Rec. 2015, 298, 386–395. [Google Scholar] [CrossRef] [PubMed]
  36. Yan, F.; Wang, X.M.; Liu, Z.C.; Pan, C.; Yuan, S.B.; Ma, Q.M. JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells. Hepatobiliary Pancreat. Dis. Int. 2010, 9, 287–295. [Google Scholar]
  37. Butterfield, L.; Zentrich, E.; Beekman, A.; Heasley, L.E. Stress- and cell type-dependent regulation of transfected c-Jun N-terminal kinase and mitogen-activated protein kinase kinase isoforms. Biochem. J. 1999, 338, 681–686. [Google Scholar] [CrossRef]
  38. Sun, R.; Xiang, T.X.; Tang, J.; Peng, W.Y.; Luo, J.; Li, L.L.; Qiu, Z.; Tan, Y.Q.; Ye, L.; Zhang, M.; et al. 19q13 KRAB zinc-finger protein ZNF471 activates MAPK10/JNK3 signaling but is frequently silenced by promoter CpG methylation in esophageal cancer. Theranostics 2020, 10, 2243–2259. [Google Scholar] [CrossRef]
  39. Finch, A.; Davis, W.; Carter, W.G.; Saklatvala, J. Analysis of mitogen-activated protein kinase pathways used by interleukin 1 in tissues in vivo: Activation of hepatic c-Jun N-terminal kinases 1 and 2, and mitogen-activated protein kinase kinases 4 and 7. Biochem. J. 2001, 353, 275–281. [Google Scholar] [CrossRef]
  40. Gorogh, T.; Berwig, J.; Scola, N.; Lippert, B.M. Differential regulation of MAPK (JNK 3) gene expression in human head and neck squamous cell carcinomas. Onkologie 2004, 27, 353–357. [Google Scholar] [CrossRef]
  41. Zang, Y.C.; Zhu, J.; Li, Q.; Tu, J.; Li, X.Q.; Hu, R.K.; Yang, D.R. miR-137-3p modulates the progression of prostate cancer by regulating the JNK3/EZH2 axis. OncoTargets Ther. 2020, 13, 7921–7932. [Google Scholar] [CrossRef] [PubMed]
  42. Wu, X.; Chen, S.; Lu, C. Amyloid precursor protein promotes the migration and invasion of breast cancer cells by regulating the MAPK signaling pathway. Int. J. Mol. Med. 2020, 45, 162–174. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Wang, D.R.; Pei, P.; Shea, F.F.; Bissonnette, C.; Nieto, K.; Din, C.; Liu, Y.Y.; Schwendeman, S.P.; Lin, Y.X.; Richard, S.; et al. Fenretinide combines perturbation of signaling kinases, cell-extracellular matrix interactions and matrix metalloproteinase activation to inhibit invasion in oral squamous cell carcinoma cells. Carcinogenesis 2022, 22, 851–864. [Google Scholar] [CrossRef] [PubMed]
  44. Rehfeldt, S.C.H.; Laufer, S.; Goettert, M.I. A highly selective in vitro JNK3 inhibitor, FMU200, restores mitochondrial membrane potential and reduces oxidative stress and apoptosis in SH-SY5Y cells. Int. J. Mol. Sci. 2021, 22, 3701. [Google Scholar] [CrossRef] [PubMed]
  45. Li, Z.T.; Zhu, G.W.; Liu, X.A.; Gao, T.F.; Fang, F.; Dou, X.D.; Li, Y.Y.; Zheng, R.Q.; Jin, H.W.; Zhang, L.R.; et al. The structure-based optimization of 3-substituted indolin-2-one derivatives as potent and isoform-selective c-Jun N-terminal kinase 3 (JNK3) inhibitors and biological evaluation. Eur. J. Med. Chem. 2023, 250, 115167. [Google Scholar] [CrossRef]
  46. Shuai, W.; Bu, F.Q.; Zhu, Y.M.; Wu, Y.Y.; Xiao, H.; Pan, X.L.; Zhang, J.F.; Sun, Q.; Wang, G.; Ouyang, L. Discovery of novel indazole chemotypes as isoform-selective JNK3 inhibitors for the treatment of Parkinson’s Disease. J. Med. Chem. 2023, 66, 1273–1300. [Google Scholar] [CrossRef]
  47. Jun, J.; Baek, J.; Kang, D.; Moon, H.; Kim, H.; Cho, H.; Hah, J.M. Novel 1,4,5,6-tetrahydrocyclopenta[d]imidazole-5-carboxamide-based JNK3 inhibitors: Design, synthesis, molecular docking, and therapeutic potential in neurodegenerative diseases. Eur. J. Med. Chem. 2023, 245, 114917. [Google Scholar] [CrossRef]
  48. Kaur, R.; Manjal, S.K.; Rawal, R.K.; Kumar, K. Recent synthetic and medicinal perspectives of tryptanthrin. Bioorganic Med. Chem. 2017, 25, 4533–4552. [Google Scholar] [CrossRef]
  49. Schepetkin, I.A.; Kovrizhina, A.R.; Stankevich, K.S.; Khlebnikov, A.I.; Kirpotina, L.N.; Quinn, M.T.; Cook, M.J. Design, synthesis and biological evaluation of novel O-substituted tryptanthrin oxime derivatives as c-Jun N-terminal kinase inhibitors. Front. Pharmacol. 2022, 13, 958687. [Google Scholar] [CrossRef]
  50. Schepetkin, I.A.; Khlebnikov, A.I.; Potapov, A.S.; Kovrizhina, A.R.; Matveevskaya, V.V.; Belyanin, M.L.; Atochin, D.N.; Zanoza, S.O.; Gaidarzhy, N.M.; Lyakhov, S.A.; et al. Synthesis, biological evaluation, and molecular modeling of 11H-indeno[1,2-b]quinoxalin-11-one derivatives and tryptanthrin-6-oxime as c-Jun N-terminal kinase inhibitors. Eur. J. Med. Chem. 2019, 161, 179–191. [Google Scholar] [CrossRef]
  51. Kirpotina, L.N.; Schepetkin, I.A.; Hammaker, D.; Kuhs, A.; Khlebnikov, A.I.; Quinn, M.T. Therapeutic effects of tryptanthrin and tryptanthrin-6-oxime in models of rheumatoid arthritis. Front. Pharmacol. 2020, 11, 1145. [Google Scholar] [CrossRef] [PubMed]
  52. Nie, Z.L.; Xia, X.L.; Zhao, Y.; Zhang, S.; Zhang, Y.W.; Wang, J.H. JNK selective inhibitor, IQ-1S, protects the mice against lipopolysaccharides-induced sepsis. Bioorgan. Med. Chem. 2021, 30, 115945. [Google Scholar] [CrossRef] [PubMed]
  53. Schepetkin, I.A.; Kirpotina, L.N.; Khlebnikov, A.I.; Hanks, T.S.; Kochetkova, I.; Pascual, D.W.; Jutila, M.A.; Quinn, M.T. Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors. Mol. Pharmacol. 2012, 81, 832–845. [Google Scholar] [CrossRef] [Green Version]
  54. Liakhov, S.A.; Schepetkin, I.A.; Karpenko, O.S.; Duma, H.I.; Haidarzhy, N.M.; Kirpotina, L.N.; Kovrizhina, A.R.; Khlebnikov, A.I.; Bagryanskaya, I.Y.; Quinn, M.T. Novel c-Jun N-Terminal Kinase (JNK) Inhibitors with an 11H-Indeno[1,2-b]quinoxalin-11-one Scaffold. Molecules 2021, 26, 5688. [Google Scholar] [CrossRef]
  55. Jia, F.C.; Zhou, Z.W.; Xu, C.; Wu, Y.D.; Wu, A.X. Divergent synthesis of quinazolin-4(3H)-ones and tryptanthrins enabled by a tert-butyl hydroperoxide/K3PO4-promoted oxidative cyclization of isatins at room temperature. Org. Lett. 2016, 18, 2942–2945. [Google Scholar] [CrossRef]
  56. Tucker, A.M.; Grundt, P. The chemistry of tryptanthrin and its derivatives. Arkivoc 2012, 1, 546–569. [Google Scholar] [CrossRef] [Green Version]
  57. Trofimov, B.A.; Schmidt, E.Y. Reactions of acetylenes in superbasic media. Recent advances. Russ. Chem. Rev. 2014, 83, 600–619. [Google Scholar] [CrossRef]
  58. Karaman, M.W.; Herrgard, S.; Treiber, D.K.; Gallant, P.; Atteridge, C.E.; Campbell, B.T.; Chan, K.W.; Ciceri, P.; Davis, M.I.; Edeen, P.T.; et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26, 127–132. [Google Scholar] [CrossRef]
  59. Ansideri, F.; Dammann, M.; Boeckler, F.M.; Koch, P. Fluorescence polarization-based competition binding assay for c-Jun N-terminal kinases 1 and 2. Anal. Biochem. 2017, 532, 26–28. [Google Scholar] [CrossRef]
  60. Guha, M.; Mackman, N. LPS induction of gene expression in human monocytes. Cell. Signal. 2001, 13, 85–94. [Google Scholar] [CrossRef]
  61. Takeuchi, O.; Akira, S. Toll-like receptors; their physiological role and signal transduction system. Int. Immunopharmacol. 2001, 1, 625–635. [Google Scholar] [CrossRef] [PubMed]
  62. Dugave, C.; Demange, L. Cis-trans isomerization of organic molecules and biomolecules: Implications and applications. Chem. Rev. 2003, 103, 2475–2532. [Google Scholar] [CrossRef] [PubMed]
  63. Blanco, F.; Alkorta, I.; Elguero, J. Barriers about double carbon-nitrogen bond in imine derivatives (aldimines, oximes, hydrazones, azines). Croat. Chem. Acta 2009, 82, 173–183. [Google Scholar]
  64. Scapin, G.; Patel, S.B.; Lisnock, J.; Becker, J.W.; LoGrasso, P.V. The structure of JNK3 in complex with small molecule inhibitors: Structural basis for potency and selectivity. Chem. Biol. 2003, 10, 705–712. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Zhao, Y.; Truhlar, D.G. The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: Two new functionals and systematic testing of four M06-class functionals and 12 other functionals. Theor. Chem. Acc. 2008, 120, 215–241. [Google Scholar] [CrossRef] [Green Version]
  66. Weiss, K.; Warren, C.H.; Wettermark, G. Cis-trans isomerization about the carbon-nitrogen double bond. Structures of the isomers of N-benzylideneaniline. J. Am. Chem. Soc. 1971, 93, 4658–4663. [Google Scholar] [CrossRef]
  67. Lakeev, A.P.; Frelikh, G.A.; Yanovskaya, E.A.; Kovrizhina, A.R.; Udut, V.V. Quantification of a promising JNK inhibitor and nitrovasodilator IQ-1 and its major metabolite in rat plasma by LC-MS/MS. Bioanalysis 2022, 14, 1423–1441. [Google Scholar] [CrossRef]
  68. Krivogorsky, B.; Nelson, A.C.; Douglas, K.A.; Grundt, P. Tryptanthrin derivatives as Toxoplasma gondii inhibitors-structure-activity-relationship of the 6-position. Bioorganic Med. Chem. Lett. 2013, 23, 1032–1035. [Google Scholar] [CrossRef]
  69. Thomsen, R.; Christensen, M.H. MolDock: A new technique for high-accuracy molecular docking. J. Med. Chem. 2006, 49, 3315–3321. [Google Scholar] [CrossRef]
  70. Neese, F.; Wennmohs, F.; Becker, U.; Riplinger, C. The ORCA quantum chemistry program package. J. Chem. Phys. 2020, 152, 224108. [Google Scholar] [CrossRef]
  71. Ásgeirsson, V.; Birgisson, B.O.; Bjornsson, R.; Becker, U.; Neese, F.; Riplinger, C.; Jónsson, H. Nudged Elastic Band Method for Molecular Reactions Using Energy-Weighted Springs Combined with Eigenvector Following. J. Chem. Theory Comput. 2021, 17, 4929–4945. [Google Scholar] [CrossRef] [PubMed]
  72. Grimme, S.; Brandenburg, J.G.; Bannwarth, C.; Hansen, A. Consistent structures and interactions by density functional theory with small atomic orbital basis sets. J. Chem. Phys. 2015, 143, 054107. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Skyner, R.E.; McDonagh, J.L.; Groom, C.R.; van Mourik, T.; Mitchell, J.B. A review of methods for the calculation of solution free energies and the modelling of systems in solution. Phys. Chem. Chem. Phys. 2015, 17, 6174–6191. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Molecules 28 04806 g001 550
Figure 1. Chemical structures of JNK inhibitors based on tryptanthrin and 11H-indeno[1,2-b]quinoxalin-11-one scaffolds with a relative high JNK isoform selectivity [49,50,51].
Figure 1. Chemical structures of JNK inhibitors based on tryptanthrin and 11H-indeno[1,2-b]quinoxalin-11-one scaffolds with a relative high JNK isoform selectivity [49,50,51].
Molecules 28 04806 g001
Molecules 28 04806 sch001 550
Scheme 1. Reagents and conditions: (A) isatoic anhydride, triethylamine, toluene, reflux, 1–2 h, 35–60%; (B) K3PO4, tert-butyl hydroperoxide (TBHP), dimethyl sulfoxide (DMSO), r.t., 20 h, 20–95%; (C) pyridine, NH2OH·HCl, reflux, 4 h, 85–95%.
Scheme 1. Reagents and conditions: (A) isatoic anhydride, triethylamine, toluene, reflux, 1–2 h, 35–60%; (B) K3PO4, tert-butyl hydroperoxide (TBHP), dimethyl sulfoxide (DMSO), r.t., 20 h, 20–95%; (C) pyridine, NH2OH·HCl, reflux, 4 h, 85–95%.
Molecules 28 04806 sch001
Molecules 28 04806 sch002 550
Scheme 2. Reagents and conditions: (A) alkylating agent, KOH, DMSO, r.t. (compounds 5a–b); (B) acylating agent, pyridine, 0 °C (compounds 5c–e).
Scheme 2. Reagents and conditions: (A) alkylating agent, KOH, DMSO, r.t. (compounds 5a–b); (B) acylating agent, pyridine, 0 °C (compounds 5c–e).
Molecules 28 04806 sch002
Molecules 28 04806 g002 550
Figure 2. Effect of compounds 4d and 4e on NF-κB/AP-1 activity and IL-6 production. Panel (A) THP-1Blue cells were pretreated with the indicated compounds or DMSO for 30 min, followed by addition of 250 ng/mL LPS or buffer for 24 h. NF-kB/AP-1 activity was monitored by measuring secreted alkaline phosphatase activity spectrophotometrically in the cell supernatants (absorbance at 655 nm). Panel (B) MonoMac-6 cells were pretreated with the indicated compounds or DMSO for 30 min, followed by addition of 250 ng/mL LPS or buffer for 24 h. Production of IL-6 in the supernatants was evaluated with ELISA. The data in each panel are presented as the mean ± S.D. of triplicate samples from one experiment that is representative of three independent experiments.
Figure 2. Effect of compounds 4d and 4e on NF-κB/AP-1 activity and IL-6 production. Panel (A) THP-1Blue cells were pretreated with the indicated compounds or DMSO for 30 min, followed by addition of 250 ng/mL LPS or buffer for 24 h. NF-kB/AP-1 activity was monitored by measuring secreted alkaline phosphatase activity spectrophotometrically in the cell supernatants (absorbance at 655 nm). Panel (B) MonoMac-6 cells were pretreated with the indicated compounds or DMSO for 30 min, followed by addition of 250 ng/mL LPS or buffer for 24 h. Production of IL-6 in the supernatants was evaluated with ELISA. The data in each panel are presented as the mean ± S.D. of triplicate samples from one experiment that is representative of three independent experiments.
Molecules 28 04806 g002
Molecules 28 04806 g003 550
Figure 3. Effect of the compounds 4d, 4e, 4h, and IQ-1S on LPS-induced c-Jun phosphorylation. Human MonoMac-6 monocytic cells were pretreated with the indicated concentrations of compounds or 0.5% DMSO for 30 min, followed by treatment with LPS (500 ng/mL) or control buffer for another 30 min. The cells were lysed, and the lysates were analyzed with ELISA for phospho-c-Jun (Ser63) and total c-Jun. The data are represented as the ratio of phospho-c-Jun to total c-Jun. The data are presented as the mean ± S.D. of triplicate samples from one experiment that is representative of three independent experiments. * Significant differences (p < 0.05) with LPS control.
Figure 3. Effect of the compounds 4d, 4e, 4h, and IQ-1S on LPS-induced c-Jun phosphorylation. Human MonoMac-6 monocytic cells were pretreated with the indicated concentrations of compounds or 0.5% DMSO for 30 min, followed by treatment with LPS (500 ng/mL) or control buffer for another 30 min. The cells were lysed, and the lysates were analyzed with ELISA for phospho-c-Jun (Ser63) and total c-Jun. The data are represented as the ratio of phospho-c-Jun to total c-Jun. The data are presented as the mean ± S.D. of triplicate samples from one experiment that is representative of three independent experiments. * Significant differences (p < 0.05) with LPS control.
Molecules 28 04806 g003
Molecules 28 04806 g004 550
Figure 4. Docking poses of compounds 4d (E) (Panel (A)) and 4q (Z) (Panel (B)) into the JNK3 binding site (PDB: 1PMV). The co-crystallized ligand SP600125 is represented by thin green sticks. Residues within 4 Å of each pose are visible. H-bonding interactions are shown in blue dashed lines.
Figure 4. Docking poses of compounds 4d (E) (Panel (A)) and 4q (Z) (Panel (B)) into the JNK3 binding site (PDB: 1PMV). The co-crystallized ligand SP600125 is represented by thin green sticks. Residues within 4 Å of each pose are visible. H-bonding interactions are shown in blue dashed lines.
Molecules 28 04806 g004
Molecules 28 04806 g005 550
Figure 5. Superimposed docking poses of the most active compounds 4c (blue), 4d (red), 4e (green), and 4h (magenta). The position of the co-crystallized ligand SP600125 (PDB: 1PMV) is shown in thin yellow sticks. Residues within 4 Å from SP600125 are shown.
Figure 5. Superimposed docking poses of the most active compounds 4c (blue), 4d (red), 4e (green), and 4h (magenta). The position of the co-crystallized ligand SP600125 (PDB: 1PMV) is shown in thin yellow sticks. Residues within 4 Å from SP600125 are shown.
Molecules 28 04806 g005
Table
Table 1. Chemical structures of starting isatins and isatoic anhydrides.
Table 1. Chemical structures of starting isatins and isatoic anhydrides.
Molecules 28 04806 i001Molecules 28 04806 i002
Compd.R1Compd.R1Compd.R2
1aH1g4-CH32aH
1b5-NO21h6-CH32b6-Br
1c5-Br1i5-CH32c6-CF3
1d5-Et1j6-OCH32d7-Br
1e5-OCH31k6-Br2e7-f
1f5-C6H51l4-Br2f7-NO2
2g6-NO2
Table
Table 2. Chemical structures of synthesized oxime derivatives and JNK binding affinity of the compounds.
Table 2. Chemical structures of synthesized oxime derivatives and JNK binding affinity of the compounds.
Molecules 28 04806 i003
Compd.R1R2R3R4R5R6JNK1JNK2JNK3Selectivity Index
Kd (µM)JNK1/JNK3JNK2/JNK3
TRYP-OxHHHHHH0.15 ± 0.081.0 ± 0.140.28 ± 0.210.153.6
4aHNO2HHHHN.B.N.B.0.86 ± 0.042>40>40
4bHBrHHHH3.2 ± 0.218.5 ± 3.20.41 ± 0.077.820.7
4cHEtHHHH2.6 ± 0.41.3 ± 0.010.49 ± 0.095.32.7
4dHOMeHHHHN.B.N.B.0.34 ± 0.03>100>100
4eHPhHHHHN.B.N.B.0.34 ± 0.04>100>100
4fHNO2HHBrHN.B.N.B.N.B.
4gMeHHHHH6.2 ± 1.814.0 ± 0.70.40 ± 0.0415.535
4hHHMeHHH0.67 ± 0.350.57 ± 0.120.23 ± 0.042.92.5
4iHHHHCF3HN.B.N.B.11.0 ± 1.4>3>3
4jHHHHBrH4.1 ± 0.67.4 ± 0.61.9 ± 0.42.23.9
4kHHHHHBrN.B.N.B.5.7 ± 1.8>6>6
4lHHHHHF1.1 ± 0.10.72 ± 0.220.43 ± 0.042.61.7
4mHHHHHNO2N.B.N.B.6.1 ± 0.4>5.6>5.6
4nHHHHNO2HN.B.N.B.8.7 ± 1.0>3.9>3.9
4oHMeHHMeH3.7 ± 0.56.9 ± 0.20.87 ± 0.164.37.9
4pMeHHMeHHN.B.N.B.N.B.
4qHOMeHHOMeHN.B.N.B.N.B.
4rHHOMeHHOMe4.6 ± 0.65.8 ± 1.63.2 ± 1.11.41.8
4sHHBrHHBrN.B.N.B.N.B.
4tHBrHHBrHN.B.N.B.N.B.
4uBrHHBrHHN.B.N.B.N.B.
Molecules 28 04806 i004
Compd.RJNK1JNK2JNK3Selectivity Index
Kd (µM)JNK1/JNK3JNK2/JNK3
5a-CH2COOEtN.B.N.B.N.B.
5b-CH(COOEt)216.5 ± 0.7N.B.N.B.
5c-COOCH31.7 ± 0.42.8 ± 0.50.70 ± 0.122.44.0
5d-COOCH2-C≡CH0.95 ± 0.031.6 ± 0.10.32 ± 0.063.05.0
5eMolecules 28 04806 i0050.47 ± 0.081.5 ± 0.60.27 ± 0.011.70.9
N.B., no binding affinity at concentrations < 30 µM.
Table
Table 3. Summary of compound cytotoxic activity and their inhibitory effects on LPS-induced NF-κB/AP-1 transcriptional activity in THP-1Blue cells and IL-6 production in MonoMac-6 cells.
Table 3. Summary of compound cytotoxic activity and their inhibitory effects on LPS-induced NF-κB/AP-1 transcriptional activity in THP-1Blue cells and IL-6 production in MonoMac-6 cells.
Compd.AP Production in THP–1BlueCytotoxicity in THP–1BlueIL–6 Production in MonoMac–6Cytotoxicity in MonoMac–6
IC50, μM
TRYP–Ox3.8 ± 1.1N.T.3.2 ± 1.2N.T.
4an.d.8.4 ± 0.9n.d.4.1 ± 0.7
4b2.1 ± 0.7N.T.15.5 ± 3.8N.T.
4c0.7 ± 0.2 N.T.n.d.13.3 ± 1.3
4d0.8 ± 0.3N.T.0.7 ± 0.1N.T.
4e1.6 ± 0.1N.T.0.17 ± 0.02N.T.
4fn.d.3.8 ± 0.9n.d.2.7 ± 0.6
4gN.A.N.T.25.2 ± 5.3N.T.
4h0.9 ± 0.2N.T.0.3 ± 0.1N.T.
4in.d.5.6 ± 1.2n.d.5.7 ± 1.2
4jn.d.12.5 ± 2.3n.d.8.2 ± 1.6
4kn.d.24.1 ± 2.70.41 ± 0.04N.T.
4l5.0 ± 0.1N.T.0.61 ± 0.04N.T.
4m8.3 ± 0.2N.T.1.9 ± 0.3N.T.
4nn.d.39.3 ± 3.19.6 ± 1.3N.T.
4o8.1 ± 0.1N.T.0.8 ± 0.1N.T.
4pN.A.N.T.N.A.N.T.
4q4.6 ± 0.3N.T.1.3 ± 0.4N.T.
4rn.d.8.3 ± 1.3n.d.4.3 ± 0.9
4sn.d.49.1 ± 8.3n.d.16.9 ± 3.4
4tn.d.6.6 ± 0.3n.d.9.2 ± 2.1
4uN.A.N.T.N.A.N.T.
5aN.A. N.T.N.A.N.T.
5bN.A. N.T.N.A.N.T.
5c8.1 ± 2.2N.T.12.4 ± 1.3N.T.
5d4.4 ± 1.6N.T.7.0 ± 0.9N.T.
5e3.5 ± 1.2 N.T.n.d.27.3 ± 1.4
N.T., no cytotoxicity was found at concentrations up to 50 µM; n.d., not determined whether a compound was cytotoxic in the cell line; N.A.: No activity was observed at the highest concentration tested (50 μM).
Table
Table 4. MolDock docking scores (DS) for the best docking poses of compounds into the binding site of JNK3 (PDB: 1PMV).
Table 4. MolDock docking scores (DS) for the best docking poses of compounds into the binding site of JNK3 (PDB: 1PMV).
CompoundDS
TRYP-Ox (Z)−62.2
TRYP-Ox (E)−34.9
4a (Z)−71.12
4a (E)−70.17
4b (Z)−73.32
4b (E)−66.26
4d (E)−84.91
4d (Z)*
4f (Z)−51.87
4f (E)−27.04
4j (E)−70.95
4j (Z)−63.44
4k (Z)−71.36
4k (E)*
4m (Z)−69.18
4m (E)−44.17
4n (Z)−65.97
4n (E)−38.77
4q (Z)−34.07
4q (E)−23.00
4s (E)−49.47
4s (Z)−21.43
4t (E)−29.88
4t (Z)−16.65
4u (E)−45.07
4u (Z)−21.39
* No docking pose with a negative DS value was found. Isomer pairs are highlighted.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Schepetkin, I.A.; Karpenko, O.S.; Kovrizhina, A.R.; Kirpotina, L.N.; Khlebnikov, A.I.; Chekal, S.I.; Radudik, A.V.; Shybinska, M.O.; Quinn, M.T. Novel Tryptanthrin Derivatives with Selectivity as c–Jun N–Terminal Kinase (JNK) 3 Inhibitors. Molecules 2023, 28, 4806. https://doi.org/10.3390/molecules28124806

AMA Style

Schepetkin IA, Karpenko OS, Kovrizhina AR, Kirpotina LN, Khlebnikov AI, Chekal SI, Radudik AV, Shybinska MO, Quinn MT. Novel Tryptanthrin Derivatives with Selectivity as c–Jun N–Terminal Kinase (JNK) 3 Inhibitors. Molecules. 2023; 28(12):4806. https://doi.org/10.3390/molecules28124806

Chicago/Turabian Style

Schepetkin, Igor A., Oleksander S. Karpenko, Anastasia R. Kovrizhina, Liliya N. Kirpotina, Andrei I. Khlebnikov, Stepan I. Chekal, Alevtyna V. Radudik, Maryna O. Shybinska, and Mark T. Quinn. 2023. "Novel Tryptanthrin Derivatives with Selectivity as c–Jun N–Terminal Kinase (JNK) 3 Inhibitors" Molecules 28, no. 12: 4806. https://doi.org/10.3390/molecules28124806

APA Style

Schepetkin, I. A., Karpenko, O. S., Kovrizhina, A. R., Kirpotina, L. N., Khlebnikov, A. I., Chekal, S. I., Radudik, A. V., Shybinska, M. O., & Quinn, M. T. (2023). Novel Tryptanthrin Derivatives with Selectivity as c–Jun N–Terminal Kinase (JNK) 3 Inhibitors. Molecules, 28(12), 4806. https://doi.org/10.3390/molecules28124806

Article Metrics

Back to TopTop